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Introduction {#sec1}
============

A long noncoding RNA (lncRNA) called *NEAT1* acts as a scaffold for paraspeckles by recruiting many RNA-binding proteins (RBPs) that have been implicated in development, cancer, and neurodegeneration, including TDP-43 and FUS ([@bib61]). Paraspeckles have been implicated in post-transcriptional regulation by association with specific mRNAs and RBPs ([@bib12], [@bib24], [@bib30], [@bib42], [@bib46]). Remarkably, paraspeckles have been identified in many types of somatic cells but not in embryonic stem cells (ESCs) ([@bib12]). Several lncRNAs and RBPs can affect differentiation of ESCs by regulating gene expression ([@bib21]), but the role of their cross-regulation in promoting efficient transitions during differentiation is unknown. Thus, investigating the recruitment of specific RBPs by *NEAT1* into paraspeckles in the context of ESC differentiation can answer the larger question of how the scaffolding of RBPs by lncRNAs is coupled to cell fate transitions and how this might coordinate the broader gene regulatory networks that establish distinct cell identities.

Here we reveal the importance of cross-regulation between *NEAT1* and TDP-43 in the context of cellular differentiation. We find that an evolutionarily conserved switch in alternative polyadenylation (APA) of *NEAT1* is regulated by TDP-43 and leads to induction of the long isoform (*NEAT1_2*), which scaffolds paraspeckles upon exit from pluripotency. We also show that TDP-43 and *NEAT1_2* have opposing functions during differentiation because of their cross-regulation: TDP-43 represses the formation of paraspeckles in pluripotent cells, whereas *NEAT1* partly sequesters TDP-43 away from mRNAs in differentiated cells. TDP-43 also globally regulates the APA of many mRNAs encoding pluripotency regulators, including the core pluripotency and reprogramming factor *Sox2*. We demonstrate that their cross-regulation is essential for the efficient functions of TDP-43 and *Neat1* in promoting states of pluripotency and differentiation, respectively. This shows how a lncRNA can act together with cross-regulated RBPs to increase the efficiency of cell fate transitions.

Results {#sec2}
=======

APA Induces Formation of Paraspeckles upon Exit from Pluripotency {#sec2.1}
-----------------------------------------------------------------

The *NEAT1* gene produces two transcripts, a short isoform that is polyadenylated and does not form paraspeckles (*NEAT1_1*) and a full-length isoform that ends with a triple helix and forms paraspeckles that scaffold various RBPs (*NEAT1_2*) ([@bib36], [@bib42]). We quantified *NEAT1* foci in human ESCs (hESCs) that were prompted to differentiate to diverse fates using single-molecule fluorescence *in situ* hybridization (FISH) probes that recognized either the region common to both isoforms or the region specific to *NEAT1_2* ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We observed a dramatic lineage-independent increase in the number of *NEAT1_2* foci in the early trophoblast-, mesoderm, mesendoderm-, and neuroectoderm-differentiated progeny of hESCs ([Figure 1](#fig1){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}B) and determined that removal of pluripotency medium (spontaneous differentiation) is sufficient to trigger paraspeckle formation ([Figure 1](#fig1){ref-type="fig"}A). As evidence of a conserved mechanism, removal of pluripotency maintenance factors (2iLIF) from the medium was also sufficient to trigger paraspeckle formation in mouse ESCs (mESCs) ([Figure 1](#fig1){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}C).Figure 1Alternative Polyadenylation of *NEAT1* Induces Paraspeckle Formation upon Differentiation and Depletion of TDP-43 in Mouse and Human ESCs(A and B) The number of paraspeckles analyzed by counting *NEAT1_1*, *NEAT1_2* (A) or *Neat1_1*, *Neat1_2* (B) double-labeled foci (based on single-molecule fluorescent *in situ* hybridization \[smFISH\] and criteria explained in [Figure S1](#mmc1){ref-type="supplementary-material"}A).(A) Undifferentiated hESCs, spontaneously differentiating cells, and BMP4-, CHIR99021-, WNT3A-, and retinoic acid (RA)-treated cells, promoting trophoblast, mesoderm, mesendoderm (primitive streak-like), and neuroectoderm fates, respectively.(B) Undifferentiated mESCs and spontaneously differentiating *iTDP-43-EGFP* mESCs untreated or treated with doxycycline to ectopically express TDP-43; more than 250 (A) and more than 200 (B) cells analyzed per group, Mann-Whitney *U* test; ^∗∗^p \< 0.001, ^∗∗∗^p \< 0.0001. Duration of treatment was as indicated.(C) Venn diagram depicting differentially expressed genes in hESCs exposed to the indicated differentiation stimuli for 24 h relative to untreated cells (n = 2 biological replicates of global RNA-seq per condition; adjusted p \< 0.01, Fisher's exact test, fold change ≥ 4). Bottom: representative mapping of *NEAT1* RNA-seq reads aligned to the two isoforms; global and nascent RNA-seq of undifferentiated hESCs and CHIR99021-treated hESCs (n = 2 biological replicates).(D and E) Percentage and representative maximum projection photomicrographs of h/mESCs exhibiting *NEAT1_1*, *NEAT1_2* (D) and *Neat1_1*, *Neat1_2* (E) isoforms analyzed as above.(D) Undifferentiated WT and *NEAT1ΔpA* line and 3-day TDP-43 small interfering RNA (siRNA)-treated hESCs (knockdown \[KD\]) maintained under pluripotency conditions.(E) Undifferentiated WT and *Neat1ΔpA* line and cTdp-43 KO (conditional knockout) mESCs 3 days following tamoxifen treatment, which leads to deletion of *Tdp-43* under pluripotency conditions. Statistical analysis and counting as in (A); scale bars, 10 μm. Red, *NEAT1_1*, *\_2*, *Neat1_1*, *\_2* probes; blue, DAPI (nuclear stain).(F) Representative mapping of *NEAT1* and *Neat1* RNA-seq reads displaying samples from TDP-43 siRNA KD or control siRNA-treated hESCs (2 days) and untreated or tamoxifen-treated Tdp-43 KO mESCs (2 days, n = 3 biological replicates) under pluripotency conditions.

To gain insights into the mechanism that contributes to *NEAT1* dynamics, we sequenced RNAs from undifferentiated hESCs and their progeny. Sequencing of nascent RNA (nascent RNA-seq) by selecting for transcripts pulse-labeled with ethynyl uridine revealed that *NEAT1_1* is expressed in undifferentiated hESCs, and *NEAT1_2* was found among the 18 transcripts that were commonly upregulated within 24 h differentiation treatment by WNT3A, a small-molecule inhibitor of GSK3 (CHIR99021), and BMP4 ([Figure 1](#fig1){ref-type="fig"}C; [Figure S1](#mmc1){ref-type="supplementary-material"}D; [Table S1](#mmc2){ref-type="supplementary-material"}). As reported for somatic cells ([@bib39], [@bib54]), we found that *NEAT1_2* is localized to the chromatin, whereas *NEAT1_1* is localized to the nucleoplasm ([Figures S1](#mmc1){ref-type="supplementary-material"}E--S1J). To determine whether the expression of *NEAT1* is post-transcriptionally regulated, we used CRISPR/Cas9-mediated editing to delete the internal polyadenylation (*ΔpA*) site of *NEAT1* in hESCs and of *Neat1* in mESCs. We found that this induced the production of *NEAT1_2* in undifferentiated hESCs or mESCs ([Figures 1](#fig1){ref-type="fig"}D, 1E, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B).

We found previously that *NEAT1* is strongly bound by TDP-43 in somatic cells ([@bib56]), which led us to inquire whether this RBP regulates *NEAT1*. Indeed, we found that overexpression of TDP-43 repressed paraspeckle formation upon spontaneous differentiation of mESCs ([Figure 1](#fig1){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}C). Conversely, depletion of *TDP-43* induced the production *NEAT1_2* and paraspeckle formation in hESCs or mESCs to a similar extent as deletion of the pA site, as detected by single-molecule imaging and RNA-seq ([Figures 1](#fig1){ref-type="fig"}D--1F; [Figure S2](#mmc1){ref-type="supplementary-material"}C). We conclude that the isoform switch of *NEAT1* is regulated by TDP-43 to coincide with the exit from pluripotency, ensuring that *NEAT1_2* scaffolds paraspeckles upon differentiation irrespective of the embryonic lineage.

*NEAT1_2* Recruits TDP-43 into Paraspeckles and Away From mRNAs {#sec2.2}
---------------------------------------------------------------

Because TDP-43 is a known paraspeckle RBP ([@bib61]), we next asked whether reciprocal regulation by *NEAT1_2* on TDP-43 takes place upon early differentiation. We used a global mRNA-RBP occupancy analysis ([@bib4], [@bib10]) to examine how induction of *NEAT1_2* in the undifferentiated state of *NEAT1ΔpA* hESCs affects the binding of RBPs to polyadenylated mRNAs ([Figure 1](#fig1){ref-type="fig"}D; [Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). Because *NEAT1_2* is not polyadenylated, it remains present in the supernatant after the removal of polyadenylated mRNAs ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Thus, the RBPs that are recruited to paraspeckles and crosslinked to *NEAT1_2* in *NEAT1ΔpA* hESCs are not expected to co-purify with polyadenylated mRNAs, and, as a result, their mRNA occupancy is expected to decrease ([Figure 2](#fig2){ref-type="fig"}A). Indeed, the mRNA occupancy of known paraspeckle proteins, including TDP-43, NONO, SFPQ, RBM14, HNRNPH3, HNRNPK, FUS, and DAZAP1 ([@bib22]), was decreased in *NEAT1ΔpA* hESCs ([Figure 2](#fig2){ref-type="fig"}B; [Figure S2](#mmc1){ref-type="supplementary-material"}G; [Table S2](#mmc3){ref-type="supplementary-material"}), demonstrating that induction of *NEAT1_2* indeed leads to partial recruitment of a cohort of RBPs into paraspeckles and away from mRNAs. In addition, we found that TDP-43, but not control RBPs, was increasingly retained in the supernatant after depletion of polyadenylated mRNAs in *NEAT1ΔpA* hESCs ([Figure 2](#fig2){ref-type="fig"}C), confirming a role of *NEAT1_2* in sequestering TDP-43 into paraspeckles.Figure 2*NEAT1_2* Recruits TDP-43 into Paraspeckles(A) A schematic overview of the mRNA-interactome analysis strategy used for identifying relocalized RBPs upon paraspeckle formation. Peptides were identified by UV crosslinking and capturing mRNA-RBP complexes using Oligod(T)25-bound magnetic beads followed by mass spectrometry. Because deletion of the *NEAT1* pA site promotes paraspeckle formation in undifferentiated hESCs ([Figure 1](#fig1){ref-type="fig"}), comparing peptide counts in *NEAT1ΔpA* with WT cells detects resulting changes in mRNA-RBP occupancy. Further details regarding global mRNA-interactome analysis are given in [Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F.(B) A Volcano plot displaying fold changes of mRNA-bound RBPs in *NEAT1ΔpA* undifferentiated hESCs and their respective statistical score (t test, n = 3 biological replicates per condition). Previously identified paraspeckle proteins are labeled red.(C) Western blot analysis of TDP-43 and non-paraspeckle control RBPs of the lysate versus the supernatant fraction after mRNA depletion by Oligod(T) capture, from UV-crosslinked WT and *NEAT1ΔpA* undifferentiated hESCs. Right: quantification (t test, n = 3, ^∗∗^p \< 0.01).(D) The positions of TDP-43 cross-linked sites (red bars) in *NEAT1* that were identified by TDP-43 iCLIP (from [@bib56]). The 1∼2-kb deleted regions (black boxes) in the *NEAT1ΔUG* cell line, and the positions of the three longest stretches of UG repeats within the transcript (yellow bars) are indicated.(E--G) Representative maximum projection photomicrographs from RNA-FISH and immunofluorescence of *NEAT1_2* and the paraspeckle markers PSPC1 (E) and TDP-43 (F) in WT and *NEAT1ΔUG* HAP-1 cells. Blue, DAPI (nuclear stain). Scale bars, 10 μm. (G) shows quantification of the TDP-43 immunofluorescence signal in DAPI and *NEAT1* segmented areas corresponding to nuclei and paraspeckles, respectively. More than 200 cells were analyzed per group; Mann-Whitney *U* test, ^∗∗∗^p \< 0.0001. The threshold was set on a ratio of TDP-43/*NEAT1* signal as described in the [STAR Methods](#sec4){ref-type="sec"}.(H) Diagram of *NEAT1* corresponding to (C), with the position of an ectopic stretch of 60 UG repeats.(I and J) Representative maximum projection photomicrographs from *NEAT1* RNA-FISH and TDP-43 immunofluorescence (I) and analysis of co-localization (J).Cell lines included WT, *NEAT1ΔUG*, and *NEAT1ΔUG+UG60* HAP1 cells. Cell numbers and statistical analysis were as in (F). Scale bars, 10 μm.

TDP-43 is known to be localized to the outer shell of paraspeckles ([@bib42], [@bib61]), but it has been unclear whether TDP-43 needs to bind to *NEAT1_2* to localize to paraspeckles. The *NEAT1_2* isoform contains three regions rich in UGUG repeats that overlap with the main peaks of TDP-43 binding ([@bib56]). We used CRISPR-Cas9 editing in the HAP1 cell line, which forms paraspeckles in the steady state, to delete these three regions from the endogenous *NEAT1* gene ([Figure 2](#fig2){ref-type="fig"}D; *NEAT1ΔUG*) that are not essential for paraspeckle assembly ([@bib65]). We confirmed that *NEAT1* foci formation and assembly of PSPC1 in paraspeckles remained intact in *NEAT1ΔUG* cells ([Figure 2](#fig2){ref-type="fig"}E). In contrast, localization of TDP-43 into paraspeckles dramatically decreased in *NEAT1ΔUG* cells ([Figures 2](#fig2){ref-type="fig"}F and 2G). To confirm that the UGUG-rich repeats in the *NEAT1_2* isoform are essential for the localization of TDP-43 to paraspeckles, we inserted a stretch of 60 UG-repeats to the 3′ end of endogenous *NEAT1ΔUG* ([Figure 2](#fig2){ref-type="fig"}H), which restored the colocalization of TDP-43 with paraspeckles ([Figures 2](#fig2){ref-type="fig"}I and 2J). Taken together, our findings indicate that TDP-43 localizes to paraspeckles because of its direct binding to the *NEAT1_2* isoform, which partially reduces its binding to polyadenylated RNAs upon paraspeckle formation.

TDP-43 Maintains Pluripotency and Enhances Somatic Cell Reprogramming {#sec2.3}
---------------------------------------------------------------------

The role of TDP-43 in suppressing paraspeckle formation in undifferentiated hESCs or mESCs and TDP-43 sequestration in differentiated cells suggested that it might be regulating pluripotency. To directly examine this, we extracted transcript abundance from 3′ mRNA-seq of conditional *Tdp-43* knockout (cTdp-43 KO) mESCs ([@bib13]; [Figure S2](#mmc1){ref-type="supplementary-material"}C). This demonstrated that many general pluripotency genes, as defined by a previous study ([@bib31]), were significantly downregulated, whereas genes that collectively classify trophectoderm differentiation were upregulated ([Figure 3](#fig3){ref-type="fig"}A; [Table S3](#mmc4){ref-type="supplementary-material"}). The only significantly upregulated pluripotency gene was *Lin28a*, but this is consistent with the fact that expression of *Lin28a* increases immediately after the exit from naive pluripotency ([@bib31]). Destabilization of pluripotency was also evident by the loss of the dome-shaped compact colony morphology in cTdp-43 KO mESCs ([Figure 3](#fig3){ref-type="fig"}B). In contrast, overexpression of TDP-43 promoted pluripotency, as indicated by prolonged expression of SSEA-1 and elevated NANOG upon spontaneous differentiation of mESCs ([Figures 3](#fig3){ref-type="fig"}C and 3D).Figure 3TDP-43 Maintains Pluripotency and Enhances Somatic Cell Reprogramming(A) Volcano plot displaying gene expression fold changes and their respective statistical score (adjusted p value, Fisher's exact test), comparing untreated and tamoxifen-treated cTdp-43 KO undifferentiated mESCs (n = 10 biological replicates per condition). Known pluripotency and trophectoderm markers are labeled red and blue, respectively (marked factors fulfilled p \< 0.01).(B) Representative photomicrographs of untreated cTdp-43 KO mESCs, following tamoxifen treatment in 2iLIF medium and following 2-day spontaneous differentiation.(C and D) Representative flow cytometry analyses of spontaneously differentiating (2 days) *iTDP-43-EGFP* mESCs that were treated with doxycycline (overexpression \[OE\]) or left untreated and immunostained for SSEA-1 (C) and NANOG (D). Non-treated cells were used for immunoglobulin G (IgG) control staining. The mean of three independent experiments is depicted on the right (error bars, SD); two-sided t test, ^∗∗∗^p \< 0.001.(E--I) Reprogramming of hiF-T secondary fibroblasts with or without (empty vector) transduction of TDP-43, cells harboring doxycycline-inducible reprogramming factors ([@bib9]) (E), number of alkaline phosphatase (AP)-positive human induced pluripotent stem cell (hiPSC) colonies emerging on day 10 and 14 of reprogramming (F and G; dots represent replicates from three independent experiments, Mann-Whitney *U* test, ^∗∗∗^p \< 0.001), representative photomicrographs (H), and TRA-1-60 flow cytometry analysis (I); n = 3 independent experiments, gating was based on an IgG control.(J and K) Reprogramming of primary human fibroblasts (J) and the number of AP-positive colonies on day 30 (dots represent replicates from three independent experiments) with or without (empty vector) transfection of TDP-43 (K); statistical analysis as in (F) and (G).

To analyze this further, we next tested whether overexpression of TDP-43 affects reprogramming of human secondary fibroblasts harboring a doxycycline-inducible OKSM (*OCT4*, *KLF4*, *SOX2*, *C-MYC*) gene cassette ([@bib9]; [Figure 3](#fig3){ref-type="fig"}E). We found that this results in a nearly 2-fold increase in the number of colonies expressing the pluripotency marker alkaline phosphatase (AP) and a 3-fold increase in cells expressing the pluripotency marker TRA-1-60 ([Figures 3](#fig3){ref-type="fig"}F--3I), indicating that TDP-43 facilitates reprogramming. Moreover, transient ectopic expression of TDP-43 during the initial phase of reprogramming of primary adult human fibroblasts led to a 5-fold increase in the number of induced pluripotent stem cell (iPSC) colonies ([Figures 3](#fig3){ref-type="fig"}J and 3K).

TDP-43 Regulates APA of Many Transcripts Important for Pluripotency, Including *SOX2* {#sec2.4}
-------------------------------------------------------------------------------------

To further understand the mechanisms whereby TDP-43 promotes pluripotency, we analyzed its global role in pA site selection, which is plausible given our previous findings regarding TDP-43's direct regulation of APA ([@bib49]). We used 3′ mRNA-seq to compare undifferentiated hESCs with mesodermal progenitors that were differentiated by activating the Wnt or β-catenin pathway using a GSK3 inhibitor ([@bib6]). We confirmed the enrichment of mesoderm gene signature and downregulation of pluripotency genes in the progenitor population by RNA-seq ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [Table S4](#mmc5){ref-type="supplementary-material"}). We also confirmed the validity of the pA sites identified by 3′ mRNA-seq ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3F). In genes that contained multiple pA sites, we defined the two pA sites with the most significant change between mesodermal progenitors and undifferentiated hESCs. Importantly, we found a correlation between the pA site changes induced by differentiation or by *TDP-43* knockdown (KD) in undifferentiated hESCs (Pearson's correlation coefficient (r) = 0.62; [Figure 4](#fig4){ref-type="fig"}A; [Table S5](#mmc6){ref-type="supplementary-material"}). This indicates that the decreased activity of TDP-43 upon early differentiation is a major cause of differentiation-induced APA.Figure 4TDP-43 Regulates APA of Genes Important for Pluripotency, Including *Sox2*(A) Scatterplot displaying relative changes of pA sites upon differentiation of hESCs ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) and changes accruing by knocking down *TDP-43* in undifferentiated hESCs for 48 h (n = 4 control short hairpin \[shCTRL\] and n = 8 sh*TDP-43* using 2 *TDP-43*-targeting short hairpin RNAs \[shRNAs\] with 4 replicates for each; adjusted p \< 0.05, Fisher's exact test). Linear regression (gray line) and the 90% confidence interval region (light blue) are shown (Pearson's correlation coefficient \[r\] = 0.62). Increased use of the proximal pA site has positive values, and decreased use has negative values, based on genes passing filtering and statistical analysis as outlined in [Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E.(B and C) Non-redundant Gene Ontology (GO) terms (B) and ground-state and general pluripotency factors (C), characterized by ([@bib31]), of genes exhibiting APA upon cTdp-43 KO in mESCs (n = 10 independent sample replicates per group; genes passing filtering and statistical analysis as outlined in [Figure S3](#mmc1){ref-type="supplementary-material"}C--S3E).(D) Representative diagrams displaying the transcript isoforms of *Sox2* upon cTdp-43 KO in mESCs and frequencies of the pA sites in *Sox2* and *SOX2* upon cTdp-43 KO in mESCs or KD of TDP-43 and 72 h CHIR99021 treatment of hESCs; samples as above.(E) The positions of TDP-43 crosslinking (red bars) in *Sox2* transcript from mESCs, as defined by iCLIP, surrounding the proximal and distal pA sites; n = 2 biological replicates ([Figure S5](#mmc1){ref-type="supplementary-material"}C) combined into a single track.(F) Western blot analysis of SOX2, TDP-43, and histone H3 following tamoxifen treatment (3 days) of cTdp-43 KO mESCs; independent replicates are shown.(G) An illustration of the *EGFP*-*SOX2* 3′ UTR reporter minigene displaying endogenous positions of the proximal and distal pA sites and the *miR-21* binding site.(H--J) Representative flow cytometry analyses of HEK293T cells with the doxycycline-inducible TDP-43 gene cassette co-transfected with *miR-21* (transfected cells were gated using tdTomato as described in [STAR Methods](#sec4){ref-type="sec"}), and the respective *EGFP-SOX2* 3′ UTR constructs: unmodified (H), harboring deletion of the proximal pA site (I), or with deletion of the *miR-21* binding site (J). Control (CTR) indicates cells that were not treated with doxycycline.(K) Boxplot depicting relative levels of *miR-21* in undifferentiated mESCs and in primitive streak (PS)-like progenitors generated by 3 d CHIR99021 treatment (n = 6 independent replicates, two sided t test; p value ^∗∗∗^ ≤ 0.001).(L) Boxplot analyses depicting levels of the *Sox2* transcript in WT mESCs and cells lacking the endogenous *miR-21* binding site in *Sox2* (*Sox2ΔmiR21*) under pluripotency conditions (top) and upon PS differentiation (bottom) (n = 5 and 6 independent replicates, two-sided t test; ^∗^p ≤ 0.01).

To systematically identify the primary RNA motifs that contribute to the regulation of APA, we analyzed the enriched sequence motifs. We identified GU-rich motifs as the highest-ranking sequences that are enriched around the pA sites that changed during hESC differentiation ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Notably, similar motifs were enriched around differential pA sites affected by KD of *TDP-43* in undifferentiated hESCs and by cTdp-43 KO in mESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Moreover, RNA maps of these motifs showed that they are located in the region upstream of the regulated pA sites ([Figures S4](#mmc1){ref-type="supplementary-material"}B--S4D), where accessory regulatory sites typically reside ([@bib16]). The similar pattern of motif enrichment for all conditions ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and the high correlation in processing changes upon differentiation or *TDP-43* KD ([Figure 4](#fig4){ref-type="fig"}A) indicated that binding of TDP-43 close to the regulated pA sites could explain a large portion of the global changes in APA that take place upon differentiation of hESCs or mESCs.

To validate the direct binding of TDP-43 to the regulated pA sites, we conducted individual nucleotide-resolution UV crosslinking and immunoprecipitation (iCLIP) experiments with TDP-43 in hESCs ([@bib33]). A direct role of TDP-43 in APA regulation was evident by the clear position-dependent dual enrichment of its binding sites around the pA sites that undergo APA following *TDP-43* KD or KO, as evident by the RNA map showing the density of its crosslinking in hESCs ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5E) or of GU-rich motifs ([Figures S5](#mmc1){ref-type="supplementary-material"}F and S5G), consistent with the previously reported RNA map in HEK293 cells ([@bib49]). Enriched binding of TDP-43 was detected close to repressed pA sites (within 100 nt) and further upstream and downstream of enhanced sites ([Figure S5](#mmc1){ref-type="supplementary-material"}F) in a pattern that was also conserved in mESCs ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Notably, TDP-43-dependent regulation of over 40% of the affected pA sites was conserved between hESCs and mESCs ([Table S5](#mmc6){ref-type="supplementary-material"}). These analyses validated the high quality and positional precision of our data and identified the RNA targets that are directly regulated by TDP-43 according to position-dependent principles.

Notably, transcripts exhibiting APA upon cTdp-43 KO were significantly enriched for the GO-term "stem cell maintenance" ([Figure 4](#fig4){ref-type="fig"}B; [Table S5](#mmc6){ref-type="supplementary-material"}). Moreover, TDP-43 dictated the APA pattern of the core naive pluripotency network, including *Sox2*, *Nr5a2*, *Esrrb*, *Klf2*, *Tfcp2l1*, *Tbx3*, *Zfp281*, *Tcf7l1*, *Zic3*, and *Tdgf1* ([@bib31]), which all changed in the same direction as upon early differentiation ([Figure 4](#fig4){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}F). One of the conserved APA events was evident in the mRNA encoding the pioneer pluripotency transcription factor *Sox2*. This gene encodes a 3′ UTR harboring two pA sites, and the transcripts showed a proximal-to-distal shift upon *TDP-43* KD in hESCs and cTdp-43 KO in mESCs and upon hESC differentiation ([Figure 4](#fig4){ref-type="fig"}D; [Table S5](#mmc6){ref-type="supplementary-material"}). The TDP-43 crosslinking pattern on the *Sox2* transcript in undifferentiated mESCs, in the 100-nt region adjacent to the distal pA site and between 100--200 nt from the proximal site ([Figure 4](#fig4){ref-type="fig"}E), is in agreement with the mode of regulation observed by the RNA map analysis ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Furthermore, TDP-43 expression correlated with the abundance of SOX2 protein, which dramatically declined following cTdp-43 KO in mESCs ([Figure 4](#fig4){ref-type="fig"}F).

To understand how TDP-43 promotes SOX2 expression, we created a minigene reporter containing the 3′ UTR of *SOX2* located downstream of *EGFP* ([Figure 4](#fig4){ref-type="fig"}G). Flow cytometry showed that overexpression of TDP-43 in HEK293T cells increased the GFP signal in the presence of *miR-21*, which could target the long isoform of *SOX2* ([Figure 4](#fig4){ref-type="fig"}H). Mutating the proximal pA site in the *SOX2* 3′ UTR made it insensitive to TDP-43, confirming that TDP-43 regulates *SOX2* expression through APA ([Figure 4](#fig4){ref-type="fig"}I). Finally, mutating the *miR-21* binding site in the reporter construct, which resides in the long isoform, ablated the effect of TDP-43 on EGFP expression ([Figure 4](#fig4){ref-type="fig"}J). Importantly, upregulation of *miR-21* took place upon primitive streak differentiation ([Figure 4](#fig4){ref-type="fig"}K), which agrees with the finding that deletion of its binding site in *Sox2* by genome editing led to a dramatic induction of *Sox2* in primitive streak progenitors ([Figure 4](#fig4){ref-type="fig"}L). These results show that TDP-43 promotes pluripotency by APA-mediated regulation of pluripotency factors, including *Sox2*.

TDP-43 Represses Formation of Paraspeckles by Regulating APA of *NEAT1* {#sec2.5}
-----------------------------------------------------------------------

Beyond direct regulation of pluripotency genes via APA, we sought to understand how TDP-43 regulates paraspeckle formation via APA of *NEAT1*. Given that the *NEAT1* isoform switch takes place upon differentiation and KD of TDP-43 ([Figure 1](#fig1){ref-type="fig"}), we speculated that downregulation of TDP-43 coincides with and, therefore, contributes to the isoform switch during differentiation. Indeed, decreased expression of TDP-43 was evident in a published RNA-seq dataset of hESCs differentiated into developmental progenitors ([@bib23]), which was inverse to the upregulation of *NEAT1_2* ([Figure 5](#fig5){ref-type="fig"}A). Moreover, we observed significantly lower levels of TDP-43 transcript and protein upon 3 days of differentiation ([Figures 5](#fig5){ref-type="fig"}B and 5C; [Figure S5](#mmc1){ref-type="supplementary-material"}H). Similarly, the expression of *NEAT1* was inversely correlated with pluripotency genes and *TDP-43* during the reprogramming of human fibroblasts to iPSCs ([Figure S5](#mmc1){ref-type="supplementary-material"}I).Figure 5TDP-43 Directly Promotes *Neat1* Polyadenylation to Repress Paraspeckles in Pluripotent Cells(A) Normalized expression of *TDP-43* and *NEAT1* in undifferentiated hESCs and differentiated developmental progenitors (transcriptome data from [@bib23]).(B and C) Quantification of TDP-43 during hESC differentiation, the transcript (B) based on [Figure 1](#fig1){ref-type="fig"}C, and on western blotting (C) using histone H3 for normalization (representative blot in [Figure S5](#mmc1){ref-type="supplementary-material"}H). Samples were derived from undifferentiated hESCs and cells differentiated toward mesoderm progenitors using CHIR99021; (B) Fisher's exact test and n = 2 and (C) t test, n = 3 independent replicates, as indicated by dots; error bars, SD; ^∗^p≤ 0.05, ^∗∗∗^p ≤ 0.001).(D) TDP-43 crosslinked positions (red bars) in the *Neat1* transcript (shown are *Neat1_1* and the 5′ region of *Neat1_2*) from mESCs analyzed by iCLIP (replicates and samples as in [Figure 4](#fig4){ref-type="fig"}E). Sequence conservation score is plotted as gray bars (n.c., not conserved).(E) Modified mESC lines lacking the endogenous binding site of TDP-43 upstream of the pA site (*Neat1Δ100nt*) or lacking the pA signal (*Neat1ΔpA*). The region deleted in the *Neat1Δ100* mESC line is highlighted and enlarged, showing the GU-rich motifs and the TDP-43 crosslinking positions in the region (based on D).(F and G) Percentage of cells exhibiting *Neat1_1* or *Neat1_2* foci (F) and number of paraspeckles in undifferentiated mESCs lines (G) and parental WT, *Neat1Δ100nt*, cTdp-43 KO mESC line 2 days following tamoxifen treatment and *Neat1ΔpA* (cell numbers analyzed, replicates, and statistical analysis as in [Figure 1](#fig1){ref-type="fig"}B).

To decipher whether TDP-43 directly regulates *NEAT1* processing, we analyzed the RNA-binding profile of TDP-43 by iCLIP ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5G). This showed that TDP-43 binds to evolutionarily conserved clusters of GU-rich motifs upstream of the pA signal in mESCs ([Figure 5](#fig5){ref-type="fig"}D). This pattern agrees with the enhancing effect of TDP-43 when binding more than 100 bp upstream of the pA site in *Sox2* ([Figure 4](#fig4){ref-type="fig"}E). To validate the direct effect, we used CRISPR-Cas9 editing of mESCs to excise a 100-nt GU-rich binding site of TDP-43 that is located 105 nt upstream of the internal *Neat1* pA site ([Figure 5](#fig5){ref-type="fig"}E; *Neat1Δ100nt* mESCs). Importantly, undifferentiated *Neat1Δ100nt* mESCs exhibited high expression of the *Neat1_2* isoform ([Figure 5](#fig5){ref-type="fig"}F) and paraspeckles ([Figure 5](#fig5){ref-type="fig"}G), which were induced to a comparable amount as in cTdp-43 KO or *Neat1ΔpA* mESCs. Moreover, we removed growth factors promoting pluripotency from *Neat1Δ100nt* and control mESC cultures to induce paraspeckles while also ectopically expressing *iTDP-43-EGFP*. The capacity of TDP-43-EGFP to repress the expression of *Neat1_2* under these conditions was reduced 2-fold in *Neat1Δ100nt* cells ([Figure S5](#mmc1){ref-type="supplementary-material"}J). Finally, *Neat1Δ100nt* mESCs exhibited an increased differentiation propensity, as evident by the decline of NANOG during spontaneous differentiation ([Figure S5](#mmc1){ref-type="supplementary-material"}K). We concluded that TDP-43 binding upstream of the *Neat1* pA site enhances the production of polyadenylated *Neat1_1*, which decreases the production of *Neat1_2* and assembly of paraspeckles upon differentiation.

*Neat1_2* Is Required for Efficient Early Differentiation by Cross-Regulation with TDP-43 {#sec2.6}
-----------------------------------------------------------------------------------------

To analyze whether *Neat1* functionally regulates the differentiation of ESCs, we excised the triple helix (TH) region at the 3′ end of the gene, which is required for stabilizing *Neat1_2* in somatic cells ([@bib62], [@bib65]). Homozygous TH deletions in mESCs significantly reduced the number of paraspeckles in differentiated cells ([Figure 6](#fig6){ref-type="fig"}A; [Figure S6](#mmc1){ref-type="supplementary-material"}A). Notably, the *in vitro* pluripotency phenotype of *Neat1ΔTH* mESCs was significantly prolonged during differentiation, as evident by higher expression of the pluripotency markers SSEA-1 and NANOG ([Figures 6](#fig6){ref-type="fig"}B and 6C), mimicking the phenotype of TDP-43 overexpression ([Figures 3](#fig3){ref-type="fig"}C and 3D).Figure 6Efficient Dissolution of Pluripotency upon Depletion of TDP-43 Requires Paraspeckles(A) Representative photomicrographs demonstrating the downregulation of *Neat1_2* paraspeckles in spontaneously differentiating mESCs by deletion of the triple helix (*ΔTH*) in the 3′ region (further results in [Figure S6](#mmc1){ref-type="supplementary-material"}A). Red, *Neat1_1* and*\_2* probes; blue, DAPI (nuclear stain). Scale bars, 10 μm.(B and C) Pluripotency assessment by SSEA-1 (B, right, quantified gated positive cells) and intracellular NANOG (C) flow cytometry of spontaneously differentiating *Neat1ΔTH* and WT mESCs (duration indicated). IgG-treated samples were used for gating positive cells (red line in B). Error bars, SD; two-sided t test; biological replicates, n = 3 per time point; ^∗^p \< 0.05, ^∗∗^p \< 0.01.(D--F) *In vivo* analysis of the developmental potency of mESCs exhibiting downregulation of paraspeckles using a 2n mESC - 4n aggregated mouse embryo complementation assay, giving rise, respectively and exclusively, to embryonic and extraembryonic tissues (D). Shown are mouse embryos (E7.75--E8.0) resulting from aggregations of *Neat1ΔTH* and *Neat1ΔpA* mESCs with 4n 2- to 4-cell-stage embryos and representative analysis of FOXA2 (E) and BRACHYURY (F) by immunostaining (n = 7 for *Neat1ΔTH* \[5 are shown in [Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C\], n = 7 for *Neat1ΔpA* \[2 are shown in [Figure S6](#mmc1){ref-type="supplementary-material"}D\], and n = 3 for parental control mESC \[2 are shown in [Figure S6](#mmc1){ref-type="supplementary-material"}E\]). Non-manipulated embryos are shown on the right. Blue, DAPI (nuclear stain). Scale bars, 100 μm. A, anterior; P, posterior; p, proximal; d, distal.(G--L) Pluripotency assessment by intracellular immunostaining flow cytometry (G--J; error bars, SD, two-sided t test in I, n = 3), RNA-seq (K; n = 3/group, Fisher's exact test), and growth kinetics (L; Mann-Whitney *U* test, n ≥ 8/group as indicated by dots) in differentiating parental cTdp-43 KO mESCs or the same line harboring *Neat1ΔTH*, treated with tamoxifen during 2.5 days of spontaneous differentiation or left untreated (all consisting of independent replicates). Also shown are representative flow cytometry plots of SOX2 (G) and quantification of gated positive cells according to the IgG control (H) and of NANOG (I and J). IgG-treated samples were used to gate the positive cells (dotted red line) and to quantify the enrichment of these cells. In (K), shown are up- and downregulated representative differentiation and pluripotency genes according to the ScoreCard panel ([@bib59], and [@bib31], respectively), comparing the impact of Tdp-43 KO in mESCs lacking *Neat1_2* (*Neat1ΔTH*) with control mESCs harboring WT *Neat1*. In (L), the width of colored intervals represents the interquartile range of the growth kinetics measurements.(M) Histogram depicting rearrangements (direction and degree) of pA sites following cTdp-43 KO in *Neat1ΔTH* mESCs compared with the respective parental WT cells (genes passing filtering and statistical analysis as outlined in [Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E; APA in the range of ±5-fold change, p \< 0.01). mESCs were treated with tamoxifen for 2.5 days or left untreated during spontaneous differentiation (n = 3 independent replicates/group).

To further assess the function of *Neat1_2* during embryonic development, we used tetraploid (4n) mouse embryo ↔ 2n mESC aggregations for generating chimera embryos exclusively derived from mESCs, whereas extra-embryonic lineages were derived from the 4n cells ([Figure 6](#fig6){ref-type="fig"}D; [@bib18]). We aggregated 4n membrane-targeted, tdTomato-expressing, 2- to 4-cell-stage embryos with wild-type (WT), *Neat1ΔpA*, or *Neat1ΔTH* mESCs, which we generated by editing IDG3.2 mESCs, a line that is routinely used for generating full-term chimeras ([@bib19]). Embryonic day 7.75 (E7.75) to E8.0 embryos derived from *Neat1ΔTH* mESCs were abnormal and exhibited defective patterning of axial mesoderm and the node, as indicated by scattered expression of FOXA2 and BRACHYURY ([Figures 6](#fig6){ref-type="fig"}E and 6F; [Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). Scattered expression of FOXA2 also suggested that the identity of definitive and visceral endoderm was perturbed ([Figure S6](#mmc1){ref-type="supplementary-material"}C).

In contrast, we did not observe morphological abnormalities of chimera embryos derived from *Neat1ΔpA* or WT mESCs ([Figures 6](#fig6){ref-type="fig"}E and 6F; [Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E), which efficiently form paraspeckles ([Figure 1](#fig1){ref-type="fig"}D). We also looked for phenotypic effects of inducing *NEAT1_2* in undifferentiated, pluripotent *NEAT1ΔpA* hESCs. Comparison with the parental cells showed that a cohort of mesoderm and endoderm markers were already expressed in the undifferentiated state, plausibly in subpopulations, despite the cells being maintained in pluripotency conditions ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Taken together, these results demonstrate that paraspeckle formation facilitates the differentiation of pluripotent cells and embryonic patterning.

Last, we analyzed the interdependence of TDP-43 and *Neat1_2* in the regulation of early spontaneous differentiation. We manipulated the two factors concomitantly by deleting the endogenous TH region in *Neat1_2* in the *cTdp-43* KO mESC line. Paraspeckles are normally increased upon inducible KO of *Tdp-43* by tamoxifen treatment of cTdp-43 KO mESCs ([Figure 1](#fig1){ref-type="fig"}E), whereas *Neat1ΔTH* mESCs are defective in the induction of paraspeckles ([Figure 6](#fig6){ref-type="fig"}A; [Figure S6](#mmc1){ref-type="supplementary-material"}A). We assessed whether deficient induction of paraspeckles upon tamoxifen treatment of the cTdp-43 KO *Neat1ΔTH* mESCs affects any of the cellular responses to TDP-43 depletion. Indeed, the key pluripotency proteins SOX2 and NANOG were downregulated to a lesser extent upon spontaneous differentiation and tamoxifen treatment of cTdp-43 KO *Neat1ΔTH* mESCs with deficient paraspeckle induction compared with cTdp-43KO mESCs [Figures 6](#fig6){ref-type="fig"}G--6J). Global transcriptome analysis revealed the same trend, evident by maintained expression of pluripotency genes and reduced expression of early differentiation genes, including *Cdx2* and *Brachyury* ([Figure 6](#fig6){ref-type="fig"}K; [Table S6](#mmc7){ref-type="supplementary-material"}). This was supported by the higher proliferative capacity of tamoxifen-treated differentiating cTdp-43 KO *Neat1ΔTH* mESCs compared with *Neat1* WT mESCs ([Figure 6](#fig6){ref-type="fig"}L). Strikingly, we observed a dramatic reduction in the number of APA-regulated genes in tamoxifen-treated cTdp-43KO *Neat1ΔTH* mESCs as compared with control cells where induction of cTdp-43KO induces paraspeckles ([Figure 6](#fig6){ref-type="fig"}M; [Table S6](#mmc7){ref-type="supplementary-material"}). Thus, decreased abundance of TDP-43 promotes dissolution of pluripotency largely through APA regulation, but induction of *Neat1_2* is required for efficient APA regulation. Collectively, we conclude that cross-regulation between *Neat1* and TDP-43 is essential for their efficient reciprocal roles in the pluripotency-differentiation transition.

Discussion {#sec3}
==========

Network modules that promote efficient cell state transitions are inherent to differentiation, regulation of organismal development, homeostasis, and regeneration ([@bib3]). Cross-regulation between regulatory factors can promote lineage bifurcation and has been associated with transcription factors, microRNAs, and signaling cascades ([@bib3], [@bib20], [@bib50]). We show here that cross-regulation between paraspeckles and TDP-43 is similarly essential for their efficient roles in promoting transition between pluripotent and differentiated cell fates. TDP-43 inhibits differentiation of ESCs, and lowers the barrier for somatic cell reprogramming, but its abundance decreases during exit from pluripotency, which changes APA of hundreds of genes, including the lncRNA *Neat1* to induce the *Neat1_2* isoform. As a result, TDP-43 is recruited into paraspeckles, which partially sequester it away from mRNAs, further decreasing the activity of TDP-43 in regulating APA during early differentiation. Induction of *Neat1_2* is essential for efficient early differentiation of ESCs and embryonic patterning during gastrulation. Thus, cross-regulation between TDP-43 and paraspeckles is reflected in the reciprocal biological functions of these two factors in promoting either the pluripotent state or differentiation of ESCs.

Changes in APA have been observed previously during differentiation processes that include myogenesis, adipogenesis, and embryogenesis ([@bib16], [@bib27]). Moreover, the core elements of the cleavage and polyadenylation complex, FIP1 ([@bib35]) and NUDT21 ([@bib7]) have been implicated in the regulation of APA during ESC differentiation. Here we used iCLIP and motif analysis to show how TDP-43 regulates APA of specific transcripts through binding to RNA motifs around the regulated pA sites ([Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}). Therefore, TDP-43 has a conserved role in promoting the production of short *Sox2* transcript, which is required for efficient expression of this pluripotency and reprogramming factor. It also promotes the short isoform of *Neat1_1*, which suppresses paraspeckle formation. This role of TDP-43 in early cell fate transitions is in line with the past observation that it is essential for murine development ([@bib52]).

When the pendulum swings in the direction of differentiation, the abundance of TDP-43 decreases to a level permissive for an isoform switch in *NEAT1*, resulting in the production of *NEAT1_2* that scaffolds paraspeckles. It has been shown previously that efficient interaction of TDP-43 and several other RBPs with *NEAT1_2* occurs as a result of phase separation into paraspeckles ([@bib38], [@bib65]). Here we have shown that induction of *NEAT1_2* in ESCs partly sequesters TDP-43 and other paraspeckle RBPs away from mRNAs, most likely because of their recruitment into the paraspeckle compartment. This sequestration could contribute to the decreased activity of TDP-43 upon early differentiation, facilitating the global shift in APA and, therefore, exit from pluripotency, which could partly explain how *Neat1_2* promotes early differentiation. It is likely that *Neat1* also acts through additional mechanisms, such as the recently reported role of *NEAT1_2* in scaffolding microprocessor and other RBPs into paraspeckles to regulate microRNA biogenesis ([@bib30]), and *Neat1_1* on its own could form "microspeckles," whose functions are currently unknown ([@bib36]). Thus, our study indicates that formation of a membraneless compartment can be regulated through the processing of its RNA scaffold to coordinate a specific developmental transition.

We have characterized developmental phenotypes of embryonic cells lacking the TH of *Neat1*, which have a reduced number of paraspeckles because of destabilized *Neat1_2*. We used the tetraploid complementation approach, which normally generates viable embryos from ESCs and is used to investigate the role of factors of interest in embryonic tissues ([@bib18]). This method enables classifications of embryonic versus extraembryonic phenotypes by circumventing pre-blastocyst developmental arrest, which has been observed upon depletion of *Neat1_2* in a recent study ([@bib28]). Tetraploid complemented embryos derived from *Neat1ΔTH* mESCs have inefficient patterning during gastrulation. Notably, we observed elevated expression of the transcription factor *Cdx2* as the major change that distinguishes the response of *Neat1ΔTH* and WT mESCs to loss of TDP-43 ([Figure 6](#fig6){ref-type="fig"}K), which agrees with the previously observed role of *Neat1* in regulating *Cdx2* ([@bib28]). The findings of both studies are also consistent with previous studies that observed decreased litter size, aberrant mammary gland morphogenesis, and smaller pups ([@bib44], [@bib55]) in *Neat1* KO mice, which lack paraspeckles ([@bib43]). This phenotype of *Neat1* KO mice is surprisingly mild, given the apparent phenotypes observed in the study, which indicates that the function of *Neat1* might be compensated by additional factors that assist cell fate transitions during *in vivo* murine development.

Beyond the mechanisms of early development, our findings are likely also relevant also for other types of cell fate transitions because both TDP-43 and *NEAT1* are broadly expressed ([@bib53]). Moreover, amyotrophic lateral sclerosis (ALS)-causing mutations in TDP-43 affect its phase separation properties ([@bib14]), which could affect its localization into paraspeckles ([@bib65]). Moreover, increased formation of paraspeckles has been observed in motor neurons of patients with ALS ([@bib45]). Therefore, cross-regulation of TDP-43 and *NEAT1* could play a role not just in development but also in diseases such as ALS and cancer, where abnormal RNA granules involving TDP-43 and *NEAT1* are a common feature ([@bib1], [@bib24], [@bib45], [@bib56]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Sox2 monoclonal antibody (D6D9) Alexa 647-conjugatedCell SignalingCat no. 5067; RRID: [AB_10828229](nif-antibody:AB_10828229){#interref165}Sox2 monoclonal AntibodyCell SignalingCat no. 2748S; RRID: 823640Nanog monoclonal AntibodyCell SignalingCat no. 8822; RRID: [AB_11217637](nif-antibody:AB_11217637){#interref170}TDP-43 polyclonal AntibodySigma-AldrichCat no. SAB4200006; RRID: [AB_10610848](nif-antibody:AB_10610848){#interref175}TDP-43 polyclonal AntibodyProteintech GroupCat no. 10782-2-AP; RRID: [AB_615042](nif-antibody:AB_615042){#interref180}GFP polyclonal AntibodyMolecular Probes/Thermo FisherCat no. A6455; RRID: [AB_221570](nif-antibody:AB_221570){#interref185}SFPQ monoclonal AntibodyThermo Fisher ScientificCat no. MA1-25325; RRID: [AB_2186931](nif-antibody:AB_2186931){#interref190}NONO polyclonal AntibodyAbcamCat no. ab70335; RRID: [AB_1269576](nif-antibody:AB_1269576){#interref195}CPEB1 polyclonal AntibodyCell SignalingCat no. 13583PSPC1 rabbit polyclonal antibody[@bib42]SRSF3 polyclonal antibodyProteinTech GroupCat no. 10916-1-AP; RRID: [AB_2185064](nif-antibody:AB_2185064){#interref200}TNPO1 monoclonal antibodyAbcamCat no. ab10303; RRID: [AB_2206878](nif-antibody:AB_2206878){#interref205}U2AF2 monoclonal antibodySigma-AldrichCat no. U4758; RRID: [AB_262122](nif-antibody:AB_262122){#interref210}Brachyury N-19 goat polyclonal antibodySanta Cruz BiotechnologiesCat no. sc17743; RRID: [AB_634980](nif-antibody:AB_634980){#interref215}Foxa2 (HNF-3β) M-20 goat polyclonalSanta Cruz BiotechnologiesCat no. sc-6554; RRID: [AB_2262810](nif-antibody:AB_2262810){#interref220}RFP rabbit polyclonalRocklandCat no. 600-401-379S; RRID: [AB_2209751](nif-antibody:AB_2209751){#interref225}Donkey anti-rabbit IgG 555InvitrogenCat no. A31572; RRID: [AB_162543](nif-antibody:AB_162543){#interref230}Donkey anti-goat IgG 488InvitrogenCat no. A11055; RRID: [AB_2534102](nif-antibody:AB_2534102){#interref235}Histone H3 polyclonal AntibodyAbcamCat no. ab1791; RRID: [AB_302613](nif-antibody:AB_302613){#interref240}Beta Actin polyclonal AntibodyNew England Biolabs/Cell Signaling antibodyCat no. 8H10D10; RRID: [AB_2242334](nif-antibody:AB_2242334){#interref245}RNAPolII-S5,S2AbcamCat no. ab103968; RRID: [AB_2687918](nif-antibody:AB_2687918){#interref250}DyLight 650-conjugated anti SSEA-1 (clone MC-480)Thermo FisherCat no. MA1-022-D650; RRID: [AB_2536696](nif-antibody:AB_2536696){#interref255}Alexa Fluor 647-conjugated anti TRA-1-60BD BioscienceCat no. 560122; RRID: [AB_1645448](nif-antibody:AB_1645448){#interref260}Alexa Fluor 647 Dk anti-Gt IgG (H+L)Thermo FisherCat no. A11058; RRID: [AB_2534105](nif-antibody:AB_2534105){#interref265}Goat anti-rabbit IgM-HRPSanta Cruz BiotechnologyCat no. sc-2030; RRID: [AB_631747](nif-antibody:AB_631747){#interref270}Goat anti-mouse IgG HRP-conjugatedDianovaCat no. 115-035-003; RRID: [AB_10015289](nif-antibody:AB_10015289){#interref275}**Chemicals, Peptides, and Recombinant Proteins**(Z)-4-HydroxytamoxifenSigma-AldrichH7904Neurobasal MediumThermo Fisher21103049DMEM F12Thermo Fisher11320033N2Thermo Fisher17502048B27Thermo Fisher17504044GlutamaxThermo Fisher350501% nonessential amino acidsThermo Fisher11400502-mercaptoethanolThermo Fisher31350-010MEK inhibitor PD0325901Axon Medchem1408GSK3 inhibitor CHIR99021Tocris4953/50LIFproduced in houseSV30160.03HITrypsin-EDTAThermo Fisher25200056HyClone Fetal Bovine Serum (FBS)GE HealthcareSV30160.03HImTeSR1 mediumStem Cell Technologies058-50MatrigelCornig356234Gentle Cell Dissociation ReagentStemCell Technologies7174KnockOut Serum ReplacementThermo Fisher10828028DMEM high glucoseThermo Fisher11965092Blue Sepharose 6 Fast Flow/ HisTrap HP columnsGE LifeSciences17-0412-01recombinant WNT3AD. Ten BergeN/ARetinoic AcidR2625-50MGSigmarecombinant BMP4R&D systems314-BPAccutaseSigma-AldrichA6964Y-27632 ROCK inhibitorR&D systems1254/10RPMI1640Thermo Fisher11875093L-GlutamineThermo Fisher25030081B27 supplement without insulinThermo FisherA1895601Lipofectamine 3000Thermo FisherL3000008Lipofectamine RNAiMAXThermo Fisher13778150PuromycinSigma-AldrichP8833-10MG,blasticidineInvivogenant-bl-05G418Invivogenant-gn-01Trizol LSLife Technologies10296028QIAzolQIAGEN79306Zymo Direct-zolZymogenR2052RNeasy Mini KitQIAGEN74104SuperScript III Reverse TranscriptaseThermo Fisher18080085RNase H, recombinantNew England BiolabsM0297SmiRNeasy Micro KitQIAGEN217084KOD FX Neo enzymeToyoboKFX-201Taqman assay master mixlThermo Fisher4369514Q5® High-Fidelity 2X Master MixThermo FisherM0492miScript PCR Starter KitQIAGEN218193formamideCalbiochem4610-OPDextran SulfateVWR9011-18-1competitor tRNA from E.coliRoche Diagnostics10109541001methanol-free formaldehydeThermo Fisher28906digoxigenin (DIG) RNA labeling kitRoche111750259102-well μ-SlidesIbidi802868-chambr SlidesIbidi80826DAPINew England Biolabs9071SSYTOX Blue Dead Cell Stain, for flow cytometryThermo FisherS34857UltraPure BSAThermo FisherAM2616vanadyl-ribonucleoside complexNew England BiolabsS1402SInsulin (human recombinant - yeast)Life Tech12585-014Transferrin (human recombinant)Sigma-AldrichT3705-1GSodium seleniteSigma-AldrichS5261-10GAscorbic acid 2-phosphateSigma-AldrichA8960-5GFGF2 (human recombinant - *E. coli*)Peprotech100-18B (1 mg)TGFB (human recombinant - *E. coli*)Peprotech100-21 (100 ug)TURBO DnaseThermo Fisheram2238RNeasy MinElute RNA cleanupQIAGEN74204protease inhibitorsMerck Millipore539134phosphatase inhibitorsSigma-Aldrich4906837001proteasome inhibitorSigma -AldrichMG132Mini-PROTEAN TGX Stain Free Gels, 4-15%Bio-Rad Laboratories456-8086Clarity Western ECL SubstrateBio-Rad Laboratories170-50605% milk powderCarl RothT145.1RNasin Plus RNase inhibitorPromegaPRN2615Lys-CWako Chemicals125-02543TrypsinPromegaV5111Igepal CA-630Sigma-AldrichI8896Triton X-100Sigma-Aldrich9002-93-1Protein A DynabeadsThermo Fisher10002DRNase IAmbionAM2295RNase ANacalai Tesque9001-99-4Proteus Clarification Mini Spin ColumnGeneronGEN-MSF500ssRNA ligaseNew England BiolabsM0204SPEG400Sigma-Aldrich202398sodium butyrateSigma-AldrichB5887-250MGascorbic acidSigma-AldrichA8960HydrocortisoneSigma-AldrichH0396InsulinThermo Fisher12585014Protan BA85 Nitrocellulose MembraneThermo FisherLC2009proteinase KRoche3115828001Phase Lock Gel Heavy tube713-2536VWRGlycoblue coprecipitantAmbion9516Costar SpinX columnCorning Incorporated8161CircLigase ssDNAEpicenterCL4111KAccuprime Supermix 1Thermo FisherAccuprime Supermix 1Agencourt AMPure XP beadsBeckman-CoulterAgencourt AMPure XP beads**Critical Commercial Assays**P3 Primary Cell 4D-Nucleofector KitLonzaV4XP-3012Nucleofector Kit VLonzaVCA-1003RiboZeroEpicenterCat\# MRZG12324TruSeq stranded total RNA Sample Prep KitIlluminaCat\# 20020599QuantSeq mRNA 3′ end sequencing kitLexogenCat\# SKU 015.96 and SKU 016.96alkaline phosphatase stainingSigma-AldrichAB0300-1KTAgilent 2100 Bioanalyzer with RNA Pico 6000 kitAgilent5067-1513Qubit dsDNA HS Assay KitThermo FisherQ32854Inside Stain kitMiltenyi Biotech130-090-477Nucleofector MEF 1 KitLonzaVPD-1004Nascent RNA Capture KitThermo FisherC10365**Deposited Data**QuantSeq and RNaseq libraries to study developmental alternative polyadenylation in hESC, its progeny and upon TDP-43 KDThis paperE-MTAB-5090. Accessible via <https://www.ebi.ac.uk/arrayexpress/>RNaseq libraries to study developmental alternative polyadenylation in human primitive streak progenitors derived from hESCs.This paperE-MTAB-5099. Accessible via <https://www.ebi.ac.uk/arrayexpress/>QuantSeq libraries to study TDP-43 dependent alternative polyadenylation in mESCs and upon paraspeckles/TDP43 perturbationsThis paperE-MTAB-5091. Accessible via <https://www.ebi.ac.uk/arrayexpress/>RNaseq libraries to study TDP-43 dependent alternative polyadenylation in mESCa and cTdp43KOThis paperE-MTAB-5097. Accessible via <https://www.ebi.ac.uk/arrayexpress/>iCLIP datasets for TDP-43This paperE-MTAB-5100. Accessible via <https://www.ebi.ac.uk/arrayexpress/>Nascent RNaseq in conjunction with Illumina TRUseq method to sequence total RNAs including short lived RNAs using highly strand-specific next-generation sequencing (NGS) librariesThis paperE-MTAB-5115QuantSeq libraries to study gene expression changes in Neat1ΔpA compared to parental undifferentiated hESCsThis paperAccessible via <https://expressrna.org/>Fractionation RNaseq in conjunction with Illumina TRUseq methodThis paperE-MTAB-5116RNaseq differentiation of hESCs to endoderm, mesoderm, ectoderm, and hepatoblasts[@bib23]GSM1112847, GSM1112845, GSM1112846, GSM1112844, GSM1112835, GSM1112833, GSM1112834, GSM1112837, GSM1124072, GSM1124072iCLIP datasets for TDP-43 in SH-SY5Y cells[@bib56]E-MTAB-527 Accessible via <https://www.ebi.ac.uk/arrayexpress/>Analysis of Pro-Inflammatory Gene Activation and RNA Processing by RNaseq of Nascent Transcripts IGSE32916 and GSE38892, accessible via GEO accession viewerMendeley dataset; Additional data composed of Sanger sequencing and confirmatory gel electrophoresis confirming the CRISPR-Cas9 edited human and mouse embryonic stem cells.This paper and Mendeley data<https://data.mendeley.com/datasets/hbr8p7n526/2>**Experimental Models: Cell Lines**HEK293 Flag-WT TDP-43 tetracycline inducible[@bib8]HeLaATCC: CCL-2RRID: CVCL_0045primary neonatal human dermal fibroblast (NHDF)ATCCCRL-2522secondary human fiboblasts (HiF-Ts)[@bib9]HAP1ATCC204508hESCs H9WicellWB66593V6.5 mESCsATCCSCRC-2011e14tg2a ICEATCCSCRC-1029*cTdp*-43 KO[@bib37]IDG3.2Hitz et al., 2007 (C57BL/6J x 129S6/SvEvTac)F1 mESC line**Experimental Models: Organisms/Strains**Mouse: CD-1Charles RiverMouse: CD-1Mouse: mT/mG[@bib41]Mouse: mT/mG**Oligonucleotides**Stellaris smFISH Probe: Human NEAT1 Middle Segment with Quasar 570StellarisSMF-2037-1-BSStellaris smFISH Probe: Human NEAT1 5\` segment conjugated to Quasar®670 or Quasar®570StellarisSMF-2036-1Stellaris smFISH Probe: Mouse Neat1 middle segment conjugated to Quasar®670StellarisCustomized productStellaris smFISH Probe: Mouse Neat1 5\` segment conjugated to Quasar®570StellarisCustomized productStealth RNAi siRNAThermo Fisher Scientific12935-200TDP-43 siRNA, 5′-GGCUCAAGCAUGGAUUCUA-DharmaconCustomized productGAPDH_FGCTCATTTCCTGGTATGACAACGGAPDH_RGAGATTCAGTGTGGTGGGGGOCT4_FCAATTTGCCAAGCTCCTGAAGOCT4_RAAAGCGGCAGATGGTCGTTMESP_FCTGCCTGAGGAGCCCAAGTMESP_RGCAGTCTGCCAAGGAACCAT_FCAACCTCACTGACGGTGAAAAAT_RACAAATTCTGGTGTGCCAAAGTTMIXL_FCCGAGTCCAGGATCCAGGTAMIXL_RCTCTGACGCCGAGACTTGGSOX17_FGGCGCAGCAGAATCCAGASOX17_RCCACGACTTGCCCAGCATLefty1_FTGTACATTGACCTGCAGGGLefty1_RACTCATAAGCCAGGAAGCCEOMES_FACAGGAGATTTCATTCGGGEOMES_RTTGTAAGACTATCATCTGGGTGGDF3_FGAGACTTATGCTACGTAAAGGAGDF3_RGGTAAAGAAAGAAACCTTGGTCFOXD3_FCTACTACAGGGAGAAGTTCCCFOXD3_RGTTGAGTGAGAGGTTGTGGNeat1.screen_FGTTTGGCTTGAATGGTGCTTNeat1.screen_RCTTCCCTCCCAGAGAGTTGANEAT1pA.screen_FTGAGCCAAGACTAGAGGGGANEAT1pA.screen_RCCTTGCTGCTCCCTTTGAAANeat1.screen_FGTTTGGCTTGAATGGTGCTTNeat1.screen_RCTTCCCTCCCAGAGAGTTGASox2Δmir21.screen_FTTAACGCAAAAACCGTGATGSox2Δmir21.screen_RGGCAGCCTGATTCCAATAACNeat1ΔTH.screen_FTTACTGCACCAGACCCTGTCNeat1ΔTH.screen_RTCCTTTGGGGAACAGGAAAGAGGapdh_FTTCACCACCATGGAGAAGGCGapdh_RCCCTTTTGGCTCCACCCTNeat1_1\_FTTGGGACAGTGGACGTGTGGNeat1_1\_RTCAAGTGCCAGCAGACAGCANeat1_2\_FGATCGGGACCCCAGTGACCTNeat1_2\_RAGCTTTCCCCAACACCCACAmmu-mir-21QIAGENMIMAT0000076: 5′UAG CUU AUC AGA CUG AUG UUG A, MIMAT0004494: 5′CAA CAC CAG UCG AUG GGC UGUTaqMan Gene Expression Assay NEAT1, isoform v2Thermo FisherHs03924655_s1TaqMan Gene Expression Assay, Gene Symbol: SOX2Thermo FisherHs01053049_s1TaqMan Gene Expression Assay, Gene Symbol: GAPDHThermo FisherHs02758991_g1TaqMan Gene Expression Assay, Neat1, Gene Symbol NEAT1 isoform v1Thermo FisherHs01008264_s1TaqMan Gene Expression Assay, Gene Symbol POU5F1Thermo FisherHs00999632_g1TaqMan® Gene Expression Assay, Gene Symbol SCARNA10Thermo FisherHs03309805_s1TaqMan® Gene Expression Assays, gene symbol Neat1v1Thermo FisherMm03455878_s1**Recombinant DNA**pmaxGFP plasmid with insertions of modified SOX2-UTRAddgene16007PMIRH21PA-1-GVO-SBISystem BiosciencesPMIRH21PA-1-GVO-SBIPX330-B/BAddgene42230pcDNA6/TRAddgene5676pCXLE-hMLNAddgene27079MIP 247 CoMiP 4in1 with shRNA p53.Addgene63726**Software and Algorithms**Bowtie2<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>TopHat2RRID: [SCR_013035](rridsoftware:SCR_013035){#intref0055}; <http://tophat.cbcb.umd.edu/>STAR[@bib17]RRID: [SCR_015899](rridsoftware:SCR_015899){#intref0065}; <https://github.com/alexdobin/STAR>CufflinksRRID: [SCR_014597](rridsoftware:SCR_014597){#intref0075}; <http://cole-trapnell-lab.github.io/cufflinks>expressRNA[@bib49]<http://www.expressrna.org/>BLAST+/2.3.0RRID: [SCR_001598](rridsoftware:SCR_001598){#intref0090}; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>RR Project for Statistical ComputingRRID: [SCR_001905](rridsoftware:SCR_001905){#intref0100}; <http://www.r-project.org/>DEXseq<https://github.com/roryk/DEXSeq/>Progenesis QI softwareversion 2.0, Nonlinear DynamicsMascot (version 2.5.1)Matrix Science<http://www.matrixscience.com/whats_new/mascot-2-5-1-patch-release.html>EdgeR[@bib48]<https://bioconductor.org/packages/release/bioc/html/edgeR.html>iCount<http://icount.fri.uni-lj.si/>HTSeq<https://htseq.readthedocs.io/en/release_0.11.1/>**Other**NEATΔpA.gRNA.up.fwdCACCGATGCAAACAATTACTGTCGTNEATΔpA.gRNA.up.revAAACACGACAGTAATTGTTTGCATCNEATΔpA.gRNA.down.fwdCACCGTGTTGAGAGTTGGTAATCATNEATΔpA.gRNA.down.revAAACATGATTACCAACTCTCAACACNeat1ΔpA.gRNA.up.fwdcaccGAAGCTTCTTAGAATTGTCANeat1ΔpA.gRNA.up.revaaacTGACAATTCTAAGAAGCTTCNeat1ΔpA.gRNA.down.fwdcaccGAGGGGAGGAAAATGGTTAGTNeat1ΔpA.gRNA.down.revaaacACTAACCATTTTCCTCCCCTCNeat1ΔTDP43.gRNA.up.fwdcaccgTTGTGAAAACCCTGTATATGNeat1ΔTDP43.gRNA.up.revaaacCATATACAGGGTTTTCACAAcNeat1ΔTDP43.gRNA.down.fwdcaccGTGAAGAAAGCTGTAACTGCNeat1ΔTDP43.gRNA.down.revaaacGCAGTTACAGCTTTCTTCACSox2Δmir21_gRNA1_upcaccgAGTATTTATCGAGATAAACASox2Δmir21_gRNA1_downaaacTGTTTATCTCGATAAATACTcSox2Δmir21_gRNA2_upcaccgATTTAGGACCGTTACAAACASox2Δmir21_gRNA2_downaaacTGTTTGTAACGGTCCTAAATcNeat1ΔTH_gRNA1_fwdcaccgaaggaagcacggtactgcaNeat1ΔTH_gRNA1_revAAACtgcagtaccgtgcttccttcNeat1ΔTH_gRNA2_fwdcaccgAGGAAAAGAAACACCTGCGGNeat1ΔTH_gRNA2_revaaacCCGCAGGTGTTTCTTTTCCTc

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by Micha Drukker (<micha.drukker@helmholtz-muenchen.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell culture {#sec4.3.1}

All mouse ESC lines e.g., e14tg2a, IDG3.2 ([@bib26]) and tamoxifen inducible (concentration of 1ug/mL or ∼2.5uM of (Z)-4-Hydroxytamoxifen, H7904, Sigma-Aldrich) *Tardbp* conditional knockout (termed cTdp-43 KO ([@bib37])) were maintained on 0.1% gelatin-coated plates in 1:1 Neurobasal (21103049) DMEM (11320033) medium containing N2 (17502048) and B27 (17504044) supplements, 1% Glutamax (35050), 1% nonessential amino acids (1140050), 0.1 mM 2-mercaptoethanol (31350-010) (all Thermo Fisher Scientific), 1 μM MEK inhibitor PD0325901 (1408, Axon Medchem), 3 μM GSK3 inhibitor CHIR99021 (4953/50 Tocris), and 1,000 U/ml LIF (produced in-house), a condition named 2iLIF. Cells were passaged using 0.25% Trypsin-EDTA (25200056, Thermo Fisher Scientific). Spontaneous differentiation was induced by the removing pathway inhibitors and LIF and replacing N2B27 supplements with 10% HyClone Fetal Bovine Serum (FBS) (SV30160.03HI GE Healthcare). Fresh medium was applied daily.

HESCs (line H9) were maintained in mTeSR1 medium (05850, STEMCELL Technologies) on Matrigel-coated plates (356234, Corning) prepared by 1:100 dilution, and 5 mL coating of 10 cm plates for 1 h at 37°C. Colonies were passaged using the gentle cell dissociation reagent (07174, StemCell Technologies). HESCs were differentiated by Trypsin-EDTA, dissociation to single cells and seeding (100,000 cells/cm2) on Matrigel-coated plates in DMEM/F12 medium (11320), supplemented with 20% KnockOut Serum Replacement (KSR; 10828028, Thermo Fisher Scientific), Glutamax, nonessential amino acids, and β-mercaptoethanol, or B27 supplemented as above with either 10 μM CHIR99021, 250ng/ml recombinant WNT3A (kindly provided by Derk ten Berge), 0.5 μM RA (R2625, Sigma-Aldrich) or 50ng/ml BMP4 (314-BP; R&D Systems). Fresh medium was applied daily.

HEK293T Flag-WT TDP-43 tetracycline inducible cell line was cultured as previously described ([@bib8]). These HEK cells were transfected using Lipofectamine 3000 (L3000001, Thermo Fisher Scientific) according to manufacturer's instructions. Fresh medium was applied daily. All cells were grown at 37oC in 5% CO2.

### Generation of h/mESC lines harboring edited NEAT1/Neat1 {#sec4.3.2}

The *NEAT1ΔpA* hESC line was generated by deleting a 500 nt region surrounding the proximal pA site including the regulatory *cis*-elements ([@bib42]). Based on [@bib47] forward and reverse gRNAs (listed below) with *BbsI* restriction site overhangs were designed, phosphorylated, annealed and cloned into *BbsI* digested Cas9-2A-GFP vector (48138 Addgene). One million cells were transfected with 5 μg plasmid pairs using the P3 Primary Cell 4D-Nucleofector Kit (V4XP-3012 Lonza) and the 4D-Nucleofector Platform (Lonza), program CB-156. 10-14 days later clones were picked, expanded and PCR-screened for identifying clones with alleles harboring deletions.

A similar approach was used for deleting 60 nt surrounding the proximal pA site in *Neat1*, 100 nt corresponding to the UGUG-rich TDP-43 binding site in *Neat1*, the region corresponding to the triple helix (*ΔTH*) in *Neat1_2*, and *miR-21* binding site in *Sox2*. 5 × 10^5^ mESCs were plated on 0.2% gelatin-coated wells of a 6 well plate, and were transfected 3 h later (Lipofectamine 3000, L3000008, Thermo Fisher Scientific) with 2 μg total plasmid DNA made of a pair of SpCas9-2A-Puro plasmids (Plasmid \#62988, Addgene), each containing single guide RNAs targeting the respective forward or reverse region in *Neat1* (listed below). 48 h later the cells were reseeded and treated with media supplemented with 1 μg/ml puromycin (P8833, Sigma-Aldrich). 5-6 days later clones were picked, expanded in 96-well plates and PCR-screened for identifying clones with alleles harboring deletions. Sequences of gRNAs and primers used for generating and screening genetically edited h/mESCs are listed in the [STAR Methods](#sec4){ref-type="sec"} section

### Generation of HAP-1 cells harboring edited NEAT1 {#sec4.3.3}

PX330-B/B containing two sgRNAs (2 ug) and pcDNA6/TR (0.2 ug) containing the blasticidin resistance gene (Thermo Fisher Scientific) were co-transfected into HAP1 cells (1.5 × 10^6^ cells) by Nucleofector Kit V (VCA-1003, Lonza) with a Nucleofector device (Lonza) using program "X-005" according to the manufacturer's instructions. To enrich the plasmid-transfected cells, the HAP1 cells were treated with 20 ug/ml blasticidin (ant-bl-05, InvivoGen) for 3 days, starting 1 day after transfection. Subsequently, the cells were diluted into 96-well plates for creating clones. Clones were lysed by proteinase K (200 ug/ml, 3115828001 Roche, 20 mM Tris-HCl pH 8.0, 5 mM EDTA, 400 mM NaCl, and 0.3% SDS at 55°C for 1 h, followed by proteinase K inactivation (95°C for 15 min). Then, the lysates were subjected to PCR analysis to amplify the genomic regions flanking the guide RNA target sites for detecting deletions or insertions using KOD FX Neo enzyme (KFX-201, TOYOBO). The indel-positive clones were further confirmed by sequencing.

Specifically, to establish HAP1 *NEAT1 ΔUG* cell line lacking three *NEAT1_2* domains (5942-7025 nt, 9201-11091 nt, and 21061-22012 nt), these domains were deleted by sequential CRISPR/Cas9-mediated deletions. First, *NEAT1_2* 5942-7025 nt (5.9-7 kb) domain was deleted by sgRNAs (GGCGGGTCGTCCTAACTAGC and CATTTAAACCTTCTTCCCCG) in HAP1 WT cells. Second, *NEAT1_2* 21061-22012 nt (21-22 kb) was deleted by introducing two sgRNAs (TACGCGGGGAAACGTGCCAC and TCCGACTTCATTTCGAGTGA) into HAP1 Δ5.9-7 kb cells. Third, *NEAT1_2* 9201-11091 nt was deleted by introducing two sgRNAs (GTACCTTATAACGTTGGATT and TATTACCTTGGCCTAGGGGG) into HAP1 Δ5.9-7 kb/21-22 kb cells to establish *NEAT1 ΔUG* cell lines. To establish HAP1 *NEAT1 ΔUG/UGx60* cell line by knocking-in UG repeats (UG x 60) into the HAP1 *NEAT1 ΔUG* cell line, PX330-B/B (2 ug) containing two sgRNAs targeting to knock-in vector (GCATCGTACGCGTACGTGTT) and NEAT1 genomic region (*NEAT1_2* 22.1 kb region) (GCGGGCGTCTGCGTGACCTC) were co-transfected with knock-in vector (pcDNA3) containing 60 TG repeats (generated by Genscript) and pcDNA6/TR plasmids (0.2 ug) into HAP1 *NEAT1 ΔUG* cells as described above. The insertion was detected by PCR and further confirmed by sequencing.

### Overexpression of TDP-43 {#sec4.3.4}

A mESC line (parental e14tg2a, kindly provided by Michael Kyba) harboring doxycycline inducible i*TDP-43-eGFP* transgene was generated by targeting the *Rosa26* locus of the A2lox.Cre line with the p2lox (plasmid \#34635, Addgene) construct cloned with TDP-43-eGFP fusion cassette. The recombination was performed as previously described ([@bib34]), and 24 h after transfection cells were selected with 250 ng/ml G418 (Invivogen, ant-gn-1) for 7 days. Clones were picked, expanded and validated. This line was subsequently modified by deleting the 100 nt corresponding to the UGUG-rich TDP-43 binding site in *Neat1*. Constitutive overexpression of TDP-43 during human fibroblast reprogramming was mediated by transduction or transfection of myc-tagged *TDP-43* ([@bib51]). Empty vector was used as a control.

### Knockdown of TDP-43 {#sec4.3.5}

2x10ˆ5 Accutase-treated single hESCs were seeded 24 h prior to transfection on Matrigel-coated 6-well plates with mTeSR1 medium supplemented with ROCK inhibitor. Per well, siRNA transfection was performed using 5 μM siRNA duplexes mixed with 5 μL Lipofectamine RNAiMAX (13778150, Thermo Fisher Scientific) and 100 μL DMEM, a solution incubated at RT for 20 min. Dharmacon, A-012394-14, TARDBP: 5′-GGCUCAAGCAUGGAUUCUA-3′ was used to target TDP-43, and a Stealth RNAi siRNA (12935-200, Thermo Fisher Scientific) was used as the negative control. Transduction was used for knocking-down of *TDP-43* via shRNAs for global analysis of PASs in parallel to the use of a luciferase shRNA vector as a control ([@bib51]).

### Plasmids {#sec4.3.6}

The 3′ UTR of *SOX2* was ectopically express by cloning the complete UTR (1263 nt including 100 nt downstream of distal pA site) immediately after the coding sequence of *eGFP* in the pmaxGFP plasmid (\#16007 addgene), producing the pmaxGFP-SOX2-UTR construct. Two variants of this plasmid were prepared by deleting the *miR-21* binding site (AAATGTCCATTGTTTATAAGCTGA) producing pmaxGFP-SOX2-UTRΔmiR21, or the regulatory sequence spanning the proximal pA site (GGAAATGGGAGGGGTGCAAAAGAGGAGAGTAAGAAACGCATGGAGAAAACCCGGTACGCTCAAAAAGAAAAAGGAAAAAAAAAAATCCCATCA) producing pmax-GFP-SOX2UTRΔpA. To ectopically express *miR-21*, the GFP sequence of plasmid PMIRH21PA-1-GVO-SBI (System Biosciences), which codes for the microRNA precursor of *miR-21*, was replaced by the sequence of the gene encoding tdTomato fluorescent protein.

### Reprogramming of human fibroblasts {#sec4.3.7}

1.5x10ˆ6 primary neonatal human dermal fibroblast (NHDF) (ATCC, CRL-2522) were transfected using the Nucleofector MEF 1 Kit (VPD-1004, Lonza) with 6μg of plasmid MIP 247 CoMiP 4in1 and 3ug of pCXLE-hMLN (63726 and 27079, Addgene). Cells were pulsed with T-020 or N-024 program using Nucleofector 2b (AAB-1001, Lonza), and were plated on Matrigel-coated plates with fibroblast medium composed of DMEM high glucose (11965092, Thermo Fisher Scientific), 10% HyClone Fetal Bovine Serum (SV30160.03HI GE Healthcare), 0.1mM sodium butyrate (B5887-250MG, Sigma Aldrich) and 64 μg/mL ascorbic acid (A8960, Sigma Aldrich). On day 2, media was changed to Essential 7 media: DMEM/F12, (11320033), Insulin (12585014) both Thermo Fisher Scientific, human recombinant Transferrin (T3705), Sodium selenite (S5261), Ascorbic acid 2-phosphate (A8960) by Sigma Aldrich and FGF2, (100-18B, Peprotech), supplemented with 0.1 mM sodium butyrate, 0.1mM Hydrocortisone (H0396, Sigma Aldrich) and 64 μg/mL ascorbic acid. Between days 10-15 first iPSC-like colonies appeared, after medium was changed to Essential 8 medium (E7 + 2ng/ml TGFbeta1) (100-21, Peprotech)) supplemented 64 μg/mL ascorbic acid in low O~2~ (5% O2) conditions. For reprogramming of secondary human fibroblasts (HiF-Ts), cells were cultured and reprogrammed as described ([@bib9]). The number of reprogrammed colonies was analyzed by alkaline phosphatase staining (AB0300-1KT, Sigma Aldrich).

### ANIMALS {#sec4.3.8}

#### Generation of chimeras {#sec4.3.8.1}

Tetraploid chimeras were generated according to standard protocols ([@bib19]). Embryos were collected from the mT/mG expressing mouse line ([@bib41]), maintained on C57/Bl6J background.

#### Animal data {#sec4.3.8.2}

Mouse keeping was done at the central facilities at HMGU in accordance with the German animal welfare legislation and acknowledged guidelines of the Society of Laboratory Animals (GV-SOLAS) and of the Federation of Laboratory Animal Science Associations (FELASA).

#### Immunofluorescence of embryos {#sec4.3.8.3}

Immunofluorescence whole-mount staining was performed in the following way. Briefly, embryos were isolated, fixed for 20 minutes using 2% PFA in PBS, permeabilized using 0.1% Triton X-100 in 0.1 M glycine pH 8.0. After blocking using 10% FCS, 3% donkey serum, 0.1% BSA, 0.1% Tween 20 for 2 h, embryos were incubated with the primary antibody o/n at 4°C in blocking solution. After several washes in PBS containing 0.1% Tween-20 (PBST) embryos were incubated with secondary antibodies (donkey anti-goat 488, donkey anti-rabbit 555 each 1:800) in blocking solution for 3 h. During the final washes with PBST, embryos were stained with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI), transferred into 15% and 30% glycerol and embedded between two coverslips using 120μ m Secure-Seal spacers (Invitrogen, S24737) and ProLong Gold antifade reagent (Invitrogen, P36930). Antibodies: Foxa2 1:1000 (Santa Cruz, sc-6554), Brachyury 1:500 (N-19, Santa Cruz, sc17743), RFP 1:1000 (Rockland, 600-401-379S).

Method Details {#sec4.4}
--------------

### RNA preparation and qRT-PCR assays {#sec4.4.1}

Total RNA was prepared from cell pellets using miRNeasy Micro Kit (217084, QIAGEN) according to the manufacturer's instructions. First-strand cDNA synthesis of 1 μg total RNA was performed using SuperScript III Reverse Transcriptase (18080085, Invitrogen), according to the manufacturer's guidelines. qRT-PCR reactions were performed using Power SYBR Green Master Mix (4367659, Thermo Fisher Scientific). *miR-21* was analyzed using the miScript protocol (218193, QIAGEN). Primers used in this study are listed in the [STAR Methods](#sec4){ref-type="sec"} section

### RNA sequencing {#sec4.4.2}

3 μg total RNA was treated with TURBO DNase (am2238, Thermo Fisher Scientific) according to manufacturer's instructions followed by RNeasy MinElute RNA cleanup (74204, QIAGEN). Microcapillary electrophoresis on Agilent 2100 Bioanalyzer with RNA Pico 6000 kit (5067-1513, Agilent) was used to analyze RNA quality (RIN values \> 8). For total RNA sequencing and per library, 1 μg RNA was depleted of rRNA using RiboZero Gold (Human/Mouse/Rat) kit followed by a cleanup step and library preparation using TruSeq Stranded Total RNA kit (RS-122-2301, Illumina) and 11 cycles of PCR, followed by purification with Agencourt AMPure XP beads (Beckman-Coulter, A63881). Libraries were evaluated on an Agilent 2100 Bioanalyzer using the DNA 1000 kit (5067-1504, Agilent) and DNA concentration was measured using a Qubit dsDNA HS Assay Kit (Q32854 Thermo Fisher Scientific). Samples were sequenced using HiSeq2500 to generate 50-nt single-end reads, sequencing depth was 20--40 Mio reads per library. For 3′mRNaseq, 0.5 μg DNase-treated RNA was used per library prepared using Lexogen QuantSeq-REV kit (016, Lexogen GmbH) according to manufacturer's instructions, and using poly(T) primer for reverse transcription. The library was sequenced using Illumina HiSeq, producing 60 nt single-end reads.

For nascent RNA-Seq, metabolic RNA labeling in living undifferentiated hESCs was performed by adding 0.4mM EU (5-ethynyl uridine) to the medium for 40 min. Total RNA was prepared using RNeasy MinElute RNA cleanup, and 10 μg of total RNA was treated by Ribo-Zero Gold rRNA removal kit, and purified using RNeasy MinElute cleanup kit. rRNA-depleted, EU-labeled RNA (0.5-1 μg) was biotinylated and captured using Click-it Nascent RNA Capture Kit (C10365, Thermo Fisher Scientific) according to manufacturer's instructions. Libraries were prepared using TruSeq Stranded Total RNA kit and sequenced on Illumina NexSeq 500 instrument with 75 cycles of single-end reads.

### Western blotting {#sec4.4.3}

Cells were trypsinized and lysed using RIPA buffer, containing phosphatase (Sigma-Aldrich, 4906837001) and protease (Merck, 539134) inhibitors. After addition of 2x SDS loading buffer with 2-Mercaptoethanol (Sigma-Aldrich, M3148) samples were heated to 95°C for 5 min. Samples were ran on Mini-PROTEAN TGX Stain Free Gels, 4%--15% (Bio-Rad Laboratories, 456-8086), and blotted using the Mini Trans-Blot Cell (Bio-Rad Laboratories, 1703930). Following 3 × 5 min washes with TBS-T, membranes were blocked with 5% milk powder (T145.1, Carl Roth) in TBS-T. Membranes were then incubated o/n at 4°C with 5% milk powder in TBS-T containing the primary antibody. After 3 × 5 min TBS-T washes, membrane was incubated with goat anti-rabbit IgM-HRP (sc-2030, Santa Cruz) or Goat anti-mouse IgG HRP-conjugated (115-035-003 Dianova) in 5% milk powder in TBS-T. Following 4 15 min washes with TBS-T the membrane was incubated for 1 min with Clarity Western ECL Substrate (170-5060, Bio-Rad Laboratories) and imaged with ChemiDoc MP System (Bio-Rad Laboratories) or exposed to X-ray film. Antibodies used are listed in the [STAR Methods](#sec4){ref-type="sec"}.

### Immunofluorescence {#sec4.4.4}

Cells were grown in Matrigel coated 8 well chamber slides (80826, Ibidi) and fixed with 4% PFA/DPBS solution (Thermo Fisher Scientific 16% Formaldehyde (w/v), Methanol-free, 28906) for 15 min at RT and permeabilized using 0.2% Triton X-100/DPBS solution for 15 min at RT. Primary and secondary antibodies were diluted per manufacturer recommended concentrations in 10%FBS/0.2% Triton X-100/DPBS and incubated respectively o/n at 4°C and 1 h at RT. The samples were washed with DAPI (50ug/ml) solution and imaged using a Zeiss Axiovert 200M epifluorescent microscope. Antibodies used are listed in the [STAR Methods](#sec4){ref-type="sec"}.

### Flow cytometry {#sec4.4.5}

Plates were washed with PBS, and cells were dissociated by Trypsin-EDTA, followed by resuspension in 2% FBS 1mM EDTA PBS buffer, and incubation with antibodies for 30-60 min on ice. Cells were centrifuged, resuspended in buffer containing SYTOX blue for dead cell exclusion and analyzed using a FACS Aria III (BD Biosciences). Cell debris were excluded by forward and side scatter gating. FlowJo was used for data analysis.

For intracellular flow cytometry mESCs were dissociated by Accutase (A6964, Sigma-Aldrich), centrifuged and resuspended in 2% of methanol-free formaldehyde (28906, Thermo Fisher Scientific) for 10 min in RT. Inside Stain kit (130-090-477, Miltenyi Biotec) was used according to manufacturer's protocol. Antibodies used are listed in the [STAR Methods](#sec4){ref-type="sec"}.

### Subcellular fractionation of hESCs {#sec4.4.6}

5-10ˆ6 cells were harvested, washed with ice-cold PBS and centrifuged at 500*g* 4°C. Cell pellets were gently resuspended in 380 μL cold cytoplasmic lysis buffer (50 mM Tris-pH 6.5, 100 mM NaCl, 300 mM Sucrose, 3 mM MgCl~2~, 0.15% NP40) supplemented with 100 U RNasin Plus RNase inhibitor (PRN2615, Promega). After incubation on ice for 10 min, cells were briefly vortexed and centrifuged at 1000*g* 4°C for 3 min. The supernatant containing the cytoplasmic fraction was transferred, and centrifuged again at 4°C 5000*g* for 2 min to remove cell debris. Immediately after centrifugation 1 mL of RNA precipitation buffer (RPS; 9.5 mL 100% EtOH with 0.5 mL 3 M Sodiumacetate) was added and the supernatant was incubated at −20°C for 3 to 5 hours until further RNA purification.

The remaining pellet was washed three times with 400 μL cytoplasmic lysis buffer supplemented with an increasing concentrations 50 mM, 200 mM and 500 mM of Ammonium sulfate (for disrupting the endoplasmic reticulum attached to the nucleus but without breaking the nuclear envelope). For each washing step, the cell suspension was centrifuged at 4°C and 5000 *g* for 2 min and the supernatant was processed for RNA extraction.

380 μL of cold Modified Wuarin-Schibler (MWS) buffer (10 mM Tris-HCl pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M Urea, 1% NP-40) supplemented with 100 U RNasin Plus RNase inhibitor was added to the remaining pellet. Samples were vortexed for 30 s, incubated on ice for 5 min, then vortexed again and kept on ice for 10 min. The suspension was centrifuged at 1000*g* 4°C for 3 min and the resulting supernatant representing the nucleoplasmic fraction was processed for RNA extraction.

The pellet was washed three times by adding 800 μL of MWS buffer, vortexing for 30 s and centrifuging at 500*g* 4°C for 2 min. 1 mL QIAzol (79306, QIAGEN) was added to the remaining chromatin pellet and after short vortexing, the suspension was stored at −20°C until further usage.

The RNA fraction in RPS buffer was vortexed for 30 s and after adding 1 μL Glycoblue coprecipitant (Life Technologies, AM9516) centrifuged at 18000 *g* 4°C for 15 min. 1 mL QIAzol was added to the partially air-dried pellet. 10 μL of 0.5 M EDTA was added to all samples and heated up to 65°C and incubated for 10 min to resuspend the pellet. After cooling down, 200 μL of chloroform / isoamyl alcohol (24:1) was added, the solution was vortexed for 30 s and then centrifuged at 18000 *g* RT for 10 min. The upper aqueous phase was transferred into a new tube and the same volume of isopropanol together with 1 μL of Glycoblue was added. After o/n incubation at −20°C, the samples were centrifuged at 18000 *g* RT. The pellets were washed once by adding 1 mL 70% EtOH and centrifuging at 18000 *g* RT for 5 min. Pellets were air-dried for 10 min and resuspended in RNase-free water. Cytoplasmic, nucleoplasmic and chromatin fractions were analyzed by RNA-sequencing as outlined above. Random primed, strand specific cDNA libraries were prepared following Illumina TruSeq total RNA protocol (above). 81 -- 92% of obtained reads aligned to the human genome allowing a single mismatch.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Single molecule (sm)FISH and paraspeckle quantification {#sec4.5.1}

Based on [@bib47], h/mESCs that were grown on Matrigel coated sterile 2-well μ-Slides (80286, Ibidi) were washed twice for 5 min with 1x PBS, and fixed using 4% methanol-free formaldehyde (10321714, Thermo Fisher Scientific) for 10 min at RT. Following additional two wash steps, cells were permeabilized using 70% ethanol for 12 h at 4°C, and were washed twice again. Then preparations were incubated for 15 min with hybridization buffer prepared using 2x saline-sodium citrate (SSC) solution / 10% deionized formamide (4610-OP, Calbiochem). Hybridization with Stellaris FISH probes was done in a total volume of 50 μl hybridization buffer containing 50 μg competitor tRNA from *E.coli* (10109541001, Roche Diagnostics), 10% Dextran Sulfate (9011-18-1, VWR), 2 mg/ml UltraPure BSA (AM2616, Thermo Fisher Scientific), and 10 mM vanadyl-ribonucleoside complex (S1402S, New England BioLabs) with probes at final concentration of 1 ng/μl. Preparations were covered with parafilm and incubated at 37°C for 5 h, and afterward washed twice with pre-warmed 2xSCC/10% formamide for 30 min at 37°C. Finally the preparations were washed twice with 1x PBS at RT, and then mounted using 10 μl ProLong Gold Antifade Reagent containing DAPI (9071S, New England Biolabs). The slides were imaged when the mounting medium was fully cured \> 12 h.

Probes were designed using the Probe Designer software from Biosearch Technologies and were provided by same vendor. Probes included were hNEAT1 middle segment conjugated to Quasar570 (SMF-2037-1), human NEAT1 5\` segment conjugated to Quasar670 or Quasar570 (SMF-2036-1), mouse Neat1 middle segment conjugated to Quasar670 and mNeat1 5\` segment conjugated to Quasar570 (sequences of probes available upon request). Quantification of hybridization signal was performed using spot detection algorithm Airlocalize ([@bib58]).

### RNA-FISH and immunofluorescence {#sec4.5.2}

RNA-FISH - immunofluorescence was performed as previously described ([@bib32], [@bib61]). The RNA probes were synthesized using T7 or SP6 RNA polymerase and a digoxigenin (DIG) RNA labeling kit (11175025910, Roche). Linearized plasmids (1 μg) containing a NEAT1 fragment (NEAT1 1-1000 nt) were used as templates. Cells were grown on coverslips (Matsunami; micro cover glass; 18 mm round; thickness, 0.16--0.19 mm) and treated with 5 uM proteasome inhibitor (MG132, Sigma-Aldrich) for 6 h to enhance NEAT1 expression ([@bib25]). Then cells were fixed with 4% paraformaldehyde/PBS at room temperature for 10 min, washed using 1 × PBS, permeabilized with 0.5% Triton X-100 (9002-93-1, Sigma-Aldrich)/PBS for 5 min, and washed three times with 1 × PBS. Subsequently, the cells were dipped in 100% ethanol for 5 min and then dried. Dehydrated coverslips were incubated with pre-hybridization solution (50% formamide, 1 × Denhardt's salt, 2 × SSC, 100 mM EDTA, 100 ug/ml yeast tRNA, and 0.01% Tween 20) at 55°C for 1 h and then incubated with hybridization solution (as above with 5% Dextran sulfate) containing the DIG-labeled RNA probes (final concentration: 100 ng/coverslip) at 55°C o/n. After hybridization, the coverslips were washed twice with pre-warmed wash buffer (50% formamide, 2 × SSC, and 0.1% Tween 20) at 55°C for 15 min. Then, excess RNA probes were digested with 10 ug/ml RNase A (9001-99-4, Nacalai Tesque) in NTET buffer (10 mM Tris-HCl \[pH 8.0\], 1 mM EDTA, 500 mM NaCl, and 0.1% Tween 20) at 37°C for 30 min. The coverslips were washed with buffer (2 × SSC and 0.01% Tween 20) at 55°C for 15 min and washed twice with a second buffer (0.1 × SSC and 0.01% Tween 20) at 55°C for 15 min. The coverslips were subsequently washed with TBST (1 × TBS containing 0.1% Tween 20) and incubated with 1 × blocking solution (Blocking reagent \[Roche\] diluted with TBST) for blocking at RT for 1 h. Then, the coverslips were incubated with primary antibodies, Anti-Digoxigenin mouse monoclonal antibody (clone 21H8, Abcam), Anti-TDP-43 rabbit polyclonal antibody (Proteintech, 1:100), anti-PSPC1 rabbit polyclonal antibody (1:1000; [@bib42]) in 1 × blocking solution at room temperature for 1 h, washed three times with TBST for 5 min, and incubated with secondary antibodies, anti-mouse IgG Alexa 488, and anti-rabbit IgG, Alexa-568 (both Thermo Fisher Scientific\]) in 1 × blocking solution at RT for 30 min, and washed three times with TBST for 5 min. The coverslips were mounted with VECTASHIELD Hard Set Mounting Medium with DAPI (Vector). Confocal images were acquired using a confocal laser scanning microscope FV1000D (Olympus). Cells were automatically counted using Fiji software. First, nuclei or paraspeckles were segmented using either DAPI or FISH staining to identify areas of interest. Then gausian blur (1.2) was applied and threshold for each object was calculated using Otsu's method. Mean intensity values or correlation coefficients were measured for the respective areas.

### iCLIP protocol and its analysis {#sec4.5.3}

The iCLIP protocol was performed as described previously ([@bib29]) with several modifications. Cells were irradiated by UV once with 160 mJ/cm^2^ using Stratalinker 1800 at 254 nm. TDP-43 was immunoprecipitated with protein A Dynabeads (10002D, Invitrogen) conjugated to rabbit-anti TDP-43 (Sigma-Aldrich, SAB4200006) or GFP (Life, Technologies, A6455). The region corresponding to 55--100kDa complexes was excised from the membrane to isolate the RNA, and sequenced using Illumina HiSeq, generating 50-nt single-end reads, sequencing depth was 15- 20 Mio reads per library. Analysis of reproducibility of cross-linked sites, identification of the significant iCLIP crosslinked clusters and z-score analysis of enriched pentamers was performed as described ([@bib56]) and data was processed by the iCount software (<https://github.com/tomazc/iCount>).

### RNA-Seq differential expression {#sec4.5.4}

To identify differentially expressed genes from RNA-Seq data, sequencing reads were mapped using TopHat2 ([@bib57]), and gene count tables were produced using HTSeq and Ensembl genome version 74. Finally, edgeR ([@bib48]) was applied to analyze P value and fold-expression changes.

### Identification of polyA sites {#sec4.5.5}

QuantSeq read data were aligned to hg19 reference genome with STAR ([@bib17]). Reads that did not align uniquely were filtered out. Identification of polyA-sites with QuantSeq relies on annealing of poly(T) primers to the polyA tails of mRNAs. To exclude cases of internal priming, where primer anneal to genomic polyA sequences, A-rich regions in vicinity of putative polyA sites were removed (\[-10..10\]). Additionally, only polyA-sites that were more than 125 nt apart from each other were treated separately, because cleavage is not a nucleotide exact process, and therefore closely spaced polyA-site were pooled. PolyA site classification was done by including those sites that were adjacent to polyA-site signals \[-100, 25\] nt.

polyA sites were categorized based on presence of a preceding polyA signal using polyAR ([@bib2]). Four classes were annotated, strong, weak, lacking polyA signal and non-categorized sites. The nucleotide composition, overlap with a published dataset of polyA-sites ([@bib15]) and efficiency of cleavage (cDNA counts) for each class of sites was analyzed, and confirmed that strong and weak sites were the most reliable sites in terms of known nucleotide composition around polyA-sites.

Strong and weak polyA-sites were used to define position-dependent polyA-site regulation by TDP-43. Of a total 28,930 polyA sites (strong + weak), 23,309 sites were annotated to genes (Ensembl version 74). 17,286 polyA-site exhibited strong signals across experiments (a minimum of 10 reads needed to be detected in either test or control sample). Summing the counts across all experiments was used as an additional filtering step to avoid sites that resulted from inefficient cleavage. Only polyA sites that exhibited \> 5% the level of another major site in the same gene were included. Since alternative long 3′ UTRs are not yet fully annotated, 5k of the intergenic region downstream of each gene were included in this analysis (however only to the middle of the downstream gene if distance \< 5kb). This led to the identification of 16,065 sites in 10,661 genes presented in ([Table S5](#mmc6){ref-type="supplementary-material"}).

### Analysis of alternative polyadenylation (APA) {#sec4.5.6}

Genes included were those exhibiting two major pA-sites (highly expressed in both test and control). Next, pA-site pairs were classified as same-exon, composite-exon or skipped-exon. For same-exon sites, the major site was compared to the sum of all other sites within the same exon (exon level). For composite-exon and skipped-exon pairs, the major site was compared to the expression of the other sites in the gene.

To estimate the level of change in expression between control and test groups, we calculated the "percent change" (pc) score, as follows:$$\text{pc} = {\text{control}_{\text{PROXIMAL}}/\text{control}_{\text{PROXIMAL} + \text{DISTAL}}}{{- \text{test}}_{\text{PROXIMAL}}/\text{test}_{\text{PROXIMAL} + \text{DISTAL}}}\left\lbrack {- 1\text{,}1} \right\rbrack$$Positive values determine a higher ratio of control versus test in proximal versus distal sites, and the negative values represent the opposite trend. Fisher's exact test was then used to determine the significance of the change. Genes were regarded as displaying significant changes in polyA site usage between test and control is Fisher's p value was \< 0.1. Lastly genes were classified as repressed (pc \< −0.1), enhanced (pc \> 0.1) and controls (abs(pc) \< 0.1 and p value \> 0.1). GO-term analysis of TDP-43 regulated alternatively polyadenylated transcripts was performed based on [@bib5].

### Visualizing position-dependent polyA site regulation using RNA-maps {#sec4.5.7}

After identifying genes exhibiting APA, summed crosslinked sites derived from iCLIP were plotted around the pA sites of repressed, enhanced and control genes ([Figures S5](#mmc1){ref-type="supplementary-material"}E--S5G). This RNA-map approach is similar to plotting RNA-maps around splice sites in alternative-splicing context ([@bib60], [@bib64]).

### mRNA/RBP occupancy (mRNA interactome capture) {#sec4.5.8}

Protocol was based on [@bib11]. ∼50X10ˆ6 undifferentiated cells in 3 replicates of WT hESC and *NEAT1ΔpA* hESC were irradiated as described for iCLIP.

### FASP digest {#sec4.5.9}

Each 10μg of RBPome were digested with a modified FASP procedure ([@bib63]). Briefly, the proteins were reduced and alkylated using dithiothreitol and iodoacetamide, diluted with one volume of UA buffer (8 M urea in 0.1M Tris/HCl pH 8.5) and then centrifuged through a 30 kDa cut-off filter device (PALL, Port Washington). Samples were washed twice with UA buffer and twice with 50 mM ammonium bicarbonate prior to digest of the immobilized proteins on the filter for 2 h at RT using 1 μg Lys-C (Wako Chemicals) and for 16 h at 37°C using 2 μg trypsin (Promega). Tryptic peptides were collected by centrifugation (10 min at 14,000 g), and the samples were acidified with 0.5% TFA and stored at −20°C.

### Mass spectrometry {#sec4.5.10}

Before loading, the samples were centrifuged for 5 min at 4°C. LC-MS/MS analysis was performed on a QExactive HF mass spectrometer (Thermo Scientific) online coupled to an Ultimate 3000 nano-RSLC (Thermo Scientific). Approximately 0.5 μg of every digested sample was automatically injected and loaded onto the trap column at a flow rate of 30 μl/min in 3% ACN/ 0.1% FA. After 5 min, the peptides were eluted from the trap column and separated on the C18 analytical column (75 μm i.d. x 25 cm, Acclaim PepMap100 C18.2 μm, 100Å, Dionex) by a 90 min gradient from 5 to 25% ACN in 0.1% FA at 300 μl/min flow rate followed by a 5 min gradient from 25% to 40% ACN in 0.1% FA. Between each sample, the column was washed with 85% ACN for 5 min followed by equilibration at 3% ACN in 0.1% FA for 18 min. MS spectra were recorded at a resolution of 60000 with an AGC target of 3e6 and a maximum injection time of 50 ms from 300 to 1500 m/z. From the MS scan, the 10 most abundant peptide ions were selected for fragmentation via HCD with a normalized collision energy of 27, an isolation window of 1.6 m/z and a dynamic exclusion of 30 s. MS/MS spectra were recorded at a resolution of 15000 with a AGC target of 1e5 and a maximum injection time of 50 ms. Intensity threshold was set to 1e4and unassigned charges and charges of +1 and \> 8 were excluded.

### Analysis of mRNA-interactome {#sec4.5.11}

Progenesis QI software (version 2.0, Nonlinear Dynamics) was used for label free quantification as described previously ([@bib40]). Briefly, profile data of the MS and MS/MS scans were transformed to peak lists with respective peak m/z values, intensities, abundances (areas under the peaks) and m/z width. After reference selection, the retention times of the other samples were aligned by automatic alignment to a maximal overlay of all features. After exclusion of all features with only one charge or more than seven charges, all remaining MS/MS spectra were exported as Mascot generic file and used for peptide identification with Mascot (version 2.5.1) in the Ensembl Human protein database. Search parameters used were: 10 ppm peptide mass tolerance and 20 mmu fragment mass tolerance, one missed cleavage allowed, carbamidomethylation was set as fixed modification, methionine oxidation and asparagine or glutamine deamidation were allowed as variable modifications. A Mascot-integrated decoy database search calculated an average false discovery of 1% when searches were performed with a mascot percolator score cut-off of 13 and an appropriate significance threshold p. Peptide assignments were re-imported into the Progenesis QI software and the abundances of all peptides allocated to each protein were summed up. Resulting normalized protein abundances were used further and compared to existing mRNA-interactome datasets obtained from HeLa ([@bib10]) and HEK293 cells ([@bib4]). As the aim of this study was not to expand the repertoire of RBPs, but rather to determine the dynamics of high confidence RBPs bound to mRNAs, we used only the overlap between published and our datasets (388 high confidence RBPs) for analysis of mRNA interactome changes upon gain of paraspeckles in *NEAT1ΔpA* cells compared to the parental line.

Data and Software Availability {#sec4.6}
------------------------------

Raw sequencing files (50 nt, single-end) have been deposited in the ArrayExpress archive (accessible at E-MTAB-5090; E-MTAB-5091; E-MTAB-5097; E-MTAB-5099; E-MTAB-5100; E-MTAB-5114, E-MTAB-5115, E-MTAB-5116) and <https://expressrna.org/> platform that enables visualization and accession of the sequencing data. Similarly, iCLIP data are deposited and available also in <https://imaps.genialis.com/> and validation of CRISPR-Cas9 modified cell lines are deposited to Mendeley data (<https://data.mendeley.com/datasets/hbr8p7n526/2>).
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